Tokushima University / Educator and Researcher Directory --- Kurahashi, Kiyoe

Field of Study

Subject of Study

Book / Paper

Book:

1.	Kiyoe Kurahashi and Itsuro Endo : るいそう, IGAKU-SHOIN Ltd.Tokyo,Japan, Tokyo, Mar. 2024.
2.	Sumiko Yoshida, 原倫世, 山口佑樹, Takeshi Kondo, 遠藤ふうり, 筒井康継, 桝田志保, Kiyoe Kurahashi, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Masahiro Abe, Kohhei Nakajima and Masahiro Abe : 急速に腫瘍が増大し悪性転化が疑われたCushing病の1例, Jun. 2019.

Academic Paper (Judged Full Paper):

1.	Tomoyo Hara, Takeshi Watanabe, Hiroki Yamagami, Kosuke Miyataka, Saya Yasui, Takahito Asai, Yohsuke Kaneko, Yukari Mitsui, Shiho Masuda, Kiyoe Kurahashi, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Soichi Honda, Akira Kondo, Munehide Matsuhisa and Ken-ichi Aihara : Development of Liver Fibrosis Represented by the Fibrosis-4 Index Is a Specific Risk Factor for Tubular Injury in Individuals with Type 2 Diabetes, Biomedicines, Vol.12, No.8, 1789, 2024. (Summary) Although hyperglycemia and hypertension are well-known risk factors for glomerular injury in individuals with type 2 diabetes (T2D), specific risk factors for tubular injury remain unclear. We aimed to clarify the differences between risk factors for glomerular injury and risk factors for tubular injury in individuals with T2D. We categorized 1243 subjects into four groups based on urinary biomarkers, including the albumin-to-creatinine ratio (uACR) and L-type fatty acid-binding protein-to-creatinine ratio (uL-ABPCR) as a normal (N) group (uACR < 30 mg/gCr and uL-FABPCR < 5 μg/gCr; n = 637), a glomerular specific injury (G) group (uACR ≥ 30 mg/gCr and uL-FABPCR < 5 μg/gCr; n = 248), a tubular specific injury (T) group (uACR < 30 mg/gCr and uL-FABPCR ≥ 5 μg/gCr; n = 90), and a dual injury (D) group (uACR ≥ 30 mg/gCr and uL-FABPCR ≥ 5 μg/gCr; n = 268). Logistic regression analysis referencing the N group revealed that BMI, current smoking, and hypertension were risk factors for the G group, creatinine (Cr) and Fibrosis-4 (FIB-4) index were risk factors for the T group, and BMI, hypertension, HbA1c, Cr, and duration of diabetes were risk factors for the D group. While hypertension was a distinct specific risk factor for glomerular injury, the FIB-4 index was a specific contributor to the prevalence of tubular injury. On the other hand, the logistic regression analysis revealed that the hepatic steatosis index (HSI) did not show any significant association with the G group, T group, or D group. Taken together, the development of liver fibrosis rather than liver steatosis is an inherent threat relating to tubular injury in individuals with T2D. (Link to Publication Site) ● Publication site (DOI): 10.3390/biomedicines12081789 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39200252 ● Summary page in Scopus @ Elsevier: 2-s2.0-85202596205 (DOI: 10.3390/biomedicines12081789, PubMed: 39200252, Elsevier: Scopus)
2.	Minae Hosoki, HORI Taiki, KANEKO Yohsuke, Kensuke Mori, Saya Yasui, Seijiro Tsuji, Hiroki Yamagami, Saki Kawata, Tomoyo Hara, Shiho Masuda, Yukari Mitsui, Kiyoe Kurahashi, Takeshi Harada, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara : Causes of In-Hospital Death and Pharmaceutical Associations with Age of Death during a 10-Year Period (2011-2020) in Individuals with and without Diabetes at a Japanese Community General Hospital., Journal of Clinical Medicine, Vol.13, No.5, 1283, 2024. (Summary) Since diabetes and its complications have been thought to exaggerate cardiorenal disease, resulting in a short lifespan, we investigated causes of death and lifespans in individuals with and without diabetes at a Japanese community general hospital during the period from 2011 to 2020. Causes of death and age of death in individuals with and those without diabetes were compared, and associations between medications used and age of death were statistically analyzed. A total of 2326 deaths were recorded during the 10-year period. There was no significant difference between the mean ages of death in individuals with and those without diabetes. Diabetic individuals had higher rates of hepato-pancreatic cancer and cardio-renal failure as causes of death. The prescription rates of antihypertensives, antiplatelets, and statins in diabetic individuals were larger than those in non-diabetic individuals. Furthermore, the use of sulfonyl urea or glinides and insulin was independently and inversely associated with the age of death. In conclusion, individuals with diabetes were treated with comprehensive pharmaceutical interventions and had life spans comparable to those of individuals without diabetes. This study's discovery of an inverse relationship between the use of insulin secretagogues or insulin and the age of death suggests that the prevention of life-threatening hypoglycemia is crucial for individuals with diabetes. (Tokushima University Institutional Repository) ● Metadata: 119252 (Link to Publication Site) ● Publication site (DOI): 10.3390/jcm13051283 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38592103 ● Search Scopus @ Elsevier (PMID): 38592103 ● Search Scopus @ Elsevier (DOI): 10.3390/jcm13051283 (Tokushima University Institutional Repository: 119252, DOI: 10.3390/jcm13051283, PubMed: 38592103)
3.	Tomoko Maruhashi, Hirokazu Miki, Kimiko Sogabe, Asuka Oda, Ryohei Sumitani, Masahiro Oura, Mamiko Takahashi, Takeshi Harada, Shiroh Fujii, Shingen Nakamura, Kiyoe Kurahashi, Itsuro Endo and Masahiro Abe : Acute suppression of translation by hyperthermia enhances anti-myeloma activity of carfilzomib, International Journal of Hematology, Vol.119, No.3, 291-302, 2024. (Summary) Hyperthermia is a unique treatment option for cancers. Multiple myeloma (MM) remains incurable and innovative therapeutic options are needed. We investigated the efficacy of hyperthermia and carfilzomib in combination against MM cells. Although MM cell lines exhibited different susceptibilities to pulsatile carfilzomib treatment, mild hyperthermia at 43℃ induced MM cell death in all cell lines in a time-dependent manner. Hyperthermia and carfilzomib cooperatively induced MM cell death even under suboptimal conditions. The pro-survival mediators PIM2 and NRF2 accumulated in MM cells due to inhibition of their proteasomal degradation by carfilzomib; however, hyperthermia acutely suppressed translation in parallel with phosphorylation of eIF2α to reduce these proteins in MM cells. Recovery of β5 subunit enzymatic activity from its immediate inhibition by carfilzomib was observed at 24 h in carfilzomib-insusceptible KMS-11, OPM-2, and RPMI8226 cells, but not in carfilzomib-sensitive MM.1S cells. However, heat treatment suppressed the recovery of β5 subunit activity in these carfilzomib-insusceptible cells. Therefore, hyperthermia re-sensitized MM cells to carfilzomib. Our results support the treatment of MM with hyperthermia in combination with carfilzomib. Further research is warranted on hyperthermia for drug-resistant extramedullary plasmacytoma. (Keyword) Humans / Multiple Myeloma / Oligopeptides / Hyperthermia, Induced (Tokushima University Institutional Repository) ● Metadata: 119321 (Link to Publication Site) ● Publication site (DOI): 10.1007/s12185-023-03706-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38252236 ● Search Scopus @ Elsevier (PMID): 38252236 ● Search Scopus @ Elsevier (DOI): 10.1007/s12185-023-03706-8 (Tokushima University Institutional Repository: 119321, DOI: 10.1007/s12185-023-03706-8, PubMed: 38252236)
4.	Kimiko Sogabe, Shingen Nakamura, Yoshiki Higa, Hirokazu Miki, Asuka Oda, Tomoko Maruhashi, Ryohei Sumitani, Masahiro Oura, Mamiko Takahashi, Masafumi Nakamura, Yusaku Maeda, Tomoyo Hara, Hiroki Yamagami, Shiroh Fujii, Kumiko Kagawa, Shuji Ozaki, Kiyoe Kurahashi, Itsuro Endo, Ken-ichi Aihara, Emiko Nakaue, Masahiro Hiasa, Jumpei Teramachi, Takeshi Harada and Masahiro Abe : Acute accumulation of PIM2 and NRF2 and recovery of β5 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors., International Journal of Hematology, Vol.119, No.3, 303-315, 2024. (Summary) Resistance to proteasome inhibitors (PIs) has emerged as an important clinical issue. We investigated the mechanisms underlying multiple myeloma (MM) cell resistance to PIs. To mimic their pharmacokinetic/pharmacodynamic (PK/PD) profiles, MM cells were treated with bortezomib and carfilzomib for 1 h at concentrations up to 400 and 1,000 nM, respectively. Susceptibility to these PIs markedly varied among MM cell lines. Pulsatile treatments with PIs suppressed translation, as demonstrated by incorporation of puromycin at 24 h in PI-susceptible MM.1S cells, but not PI-resistant KMS-11 cells. Inhibition of β5 subunit activity decreased at 24 h in KMS-11 cells, even with the irreversible PI carfilzomib, but not under suppression of protein synthesis with cycloheximide. Furthermore, the proteasome-degradable pro-survival factors PIM2 and NRF2 acutely accumulated in MM cells subjected to pulsatile PI treatments. Accumulated NRF2 was trans-localized into the nucleus to induce the expression of its target gene, HMOX1, in MM cells. PIM and Akt inhibition restored the anti-MM effects of PIs, even against PI-resistant KMS-11 cells. Collectively, these results suggest that increased synthesis of β5 proteasome subunit and acute accumulation of PIM2 and NRF2 reduce the anti-MM effects of PIs. (Keyword) Humans / Proteasome Inhibitors / NF-E2-Related Factor 2 / Multiple Myeloma / Proteasome Endopeptidase Complex / Drug Resistance, Neoplasm / Cell Line, Tumor / Bortezomib / Antineoplastic Agents / Proto-Oncogene Proteins / Protein Serine-Threonine Kinases (Tokushima University Institutional Repository) ● Metadata: 119384 (Link to Publication Site) ● Publication site (DOI): 10.1007/s12185-023-03705-9 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38245883 ● Search Scopus @ Elsevier (PMID): 38245883 ● Search Scopus @ Elsevier (DOI): 10.1007/s12185-023-03705-9 (Tokushima University Institutional Repository: 119384, DOI: 10.1007/s12185-023-03705-9, PubMed: 38245883)
5.	Hiroki Yamagami, Tomoyo Hara, Saya Yasui, Minae Hosoki, Taiki Hori, Yousuke Kaneko, Yukari Mitsui, Kiyoe Kurahashi, Takeshi Harada, Sumiko Yoshida, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Cross-Sectional and Longitudinal Associations between Skin Autofluorescence and Tubular Injury Defined by Urinary Excretion of Liver-Type Fatty Acid-Binding Protein in People with Type 2 Diabetes., Biomedicines, Vol.11, No.11, 3020, 2023. (Summary) = 0.026). In conclusion, SAF is positively correlated with uL-FABP but not with uACR in people with T2D. Thus, there is a possibility that SAF can serve as a novel predictor for the development of diabetic tubular injury. (Keyword) skin autofluorescence / type 2 diabetes / diabetic kidney disease / albuminuria / tubular injury / L-FABP (Tokushima University Institutional Repository) ● Metadata: 119108 (Link to Publication Site) ● Publication site (DOI): 10.3390/biomedicines11113020 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38002020 ● CiNii @ National Institute of Informatics (CRID): 1870302167614368000 ● Summary page in Scopus @ Elsevier: 2-s2.0-85178346619 (Tokushima University Institutional Repository: 119108, DOI: 10.3390/biomedicines11113020, PubMed: 38002020, CiNii: 1870302167614368000, Elsevier: Scopus)
6.	Saya Yasui, Yousuke Kaneko, Hiroki Yamagami, Minae Hosoki, Taiki Hori, Akihiro Tani, Tomoyo Hara, Kiyoe Kurahashi, Takeshi Harada, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa, Hiroyasu Mori, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Takeshi Soeki and Ken-ichi Aihara : Dehydroepiandrosterone Sulfate, an Adrenal Androgen, Is Inversely Associated with Prevalence of Dynapenia in Male Individuals with Type 2 Diabetes., Metabolites, Vol.13, No.11, 1129, 2023. (Summary) Dehydroepiandrosterone sulfate (DHEAS) is thought to be associated with life expectancy and anti-aging. Although skeletal muscle disorders are often found in diabetic people, the clinical significance of DHEAS in skeletal muscle remains unclear. Therefore, we aimed to determine whether DHEAS is associated with the development of skeletal muscle disorders in individuals with type 2 diabetes (T2D). A cross-sectional study was conducted in 361 individuals with T2D. Serum DHEAS levels, skeletal muscle mass index (SMI), handgrip strength (HS), and gait speed (GS) were measured in the participants. Pre-sarcopenia, sarcopenia, and dynapenia were defined according to the definitions of the AWGS 2019 criteria. DHEAS level was positively associated with HS but not with SMI or GS after adjustment of confounding factors. Multiple logistic regression analyses in total subjects showed that DHEAS level had an inverse association with the prevalence of dynapenia but not with the prevalence of pre-sarcopenia or sarcopenia. Furthermore, a significant association between DHEAS level and dynapenia was found in males but not in females. ROC curve analysis indicated that cutoff values of serum DHEAS for risk of dynapenia in males was 92.0 μg/dL. Therefore, in male individuals with T2D who have low serum levels of DHEAS, adequate exercise might be needed to prevent dynapenia. (Tokushima University Institutional Repository) ● Metadata: 119107 (Link to Publication Site) ● Publication site (DOI): 10.3390/metabo13111129 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37999225 ● CiNii @ National Institute of Informatics (CRID): 1870583643033891840 ● Summary page in Scopus @ Elsevier: 2-s2.0-85178271509 (Tokushima University Institutional Repository: 119107, DOI: 10.3390/metabo13111129, PubMed: 37999225, CiNii: 1870583643033891840, Elsevier: Scopus)
7.	Hiroyasu Mori, 谷口諭, 玉木悠, 野村友美, 鈴木麗子, Akio Kuroda, 明比祐子, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, 白神敦久, 田蒔基行, 天満仁, 長島伸光, 比木武 and Munehide Matsuhisa : 2型糖尿病患者のPersonal Health Recordを用いたセルフモニタリングに自動支援メッセージが与える効果:探索的ランダム化比較試験, 日本糖尿病インフォマティクス学会誌, Vol.22, No.2, 7-18, 2023.
8.	Masahiro Oura, Takeshi Harada, Asuka Oda, Jumpei Teramachi, Atsushi Nakayama, Ryohei Sumitani, Yusuke Inoue, Yusaku Maeda, Kimiko Sogabe, Maruhashi Tomoko, Mamiko Takahashi, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Shingen Nakamura, Tomoyo Hara, Hiroki Yamagami, Kiyoe Kurahashi, Itsuro Endo, Hiroo Hasegawa, Hiroshi Fujiwara and Masahiro Abe : Therapeutic efficacy of the resorcylic acid lactone LL-Z1640-2 for adult T-cell leukaemia/lymphoma, eJHaem, Vol.4, No.3, 667-678, 2023. (Summary) Adult T-cell leukaemia/lymphoma (ATL) remains incurable. The NF-κB and interferon regulatory factor 4 (IRF4) signalling pathways are among the critical survival pathways for the progression of ATL. TGF-β-activated kinase 1 (TAK1), an IκB kinase-activating kinase, triggers the activation of NF-κB. The resorcylic acid lactone LL-Z1640-2 is a potent irreversible inhibitor of TAK1/extracellular signal-regulated kinase 2 (ERK2). We herein examined the therapeutic efficacy of LL-Z1640-2 against ATL. LL-Z1640-2 effectively suppressed the in vivo growth of ATL cells. It induced in vitro apoptosis and inhibited the nuclear translocation of p65/RelA in ATL cells. The knockdown of strongly induced ATL cell death while downregulating MYC. LL-Z1640-2 as well as the NF-κB inhibitor BAY11-7082 decreased the expression of IRF4 and MYC at the protein and mRNA levels, indicating the suppression of the NF-κB-IRF4-MYC axis. The treatment with LL-Z1640-2 also mitigated the phosphorylation of p38 MAPK along with the expression of CC chemokine receptor 4. Furthermore, the inhibition of STAT3/5 potentiated the cytotoxic activity of LL-Z1640-2 against IL-2-responsive ATL cells in the presence of IL-2. Therefore, LL-Z1640-2 appears to be an effective treatment for ATL. Further studies are needed to develop more potent compounds that retain the active motifs of LL-Z1640-2. (Link to Publication Site) ● Publication site (DOI): 10.1002/jha2.758 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37601887 ● Search Scopus @ Elsevier (PMID): 37601887 ● Search Scopus @ Elsevier (DOI): 10.1002/jha2.758 (DOI: 10.1002/jha2.758, PubMed: 37601887)
9.	Shiho Masuda, Tomoyo Hara, Hiroki Yamagami, Yukari Mitsui, Kiyoe Kurahashi, Sumiko Yoshida, Takeshi Harada, Toshiki Otoda, Tomoyuki Yuasa, Shingen Nakamura, Akio Kuroda, Itsuro Endo, Toshio Matsumoto, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Vascular Endothelial Function Is Associated with eGFR Slope in Female and Non-Smoking Male Individuals with Cardiovascular Risk Factors: A Pilot Study on the Predictive Value of FMD for Renal Prognosis., Journal of Atherosclerosis and Thrombosis, 2023. (Summary) In individuals with cardiovascular risk factors, evaluation of vascular endothelial function enables prediction of renal prognosis in females and non-smoking males. (Tokushima University Institutional Repository) ● Metadata: 118250 (Link to Publication Site) ● Publication site (DOI): 10.5551/jat.63987 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37081616 ● Search Scopus @ Elsevier (PMID): 37081616 ● Search Scopus @ Elsevier (DOI): 10.5551/jat.63987 (Tokushima University Institutional Repository: 118250, DOI: 10.5551/jat.63987, PubMed: 37081616)
10.	Taiki Hori, Shingen Nakamura, Hiroki Yamagami, Saya Yasui, Minae Hosoki, Tomoyo Hara, Yukari Mitsui, Shiho Masuda, Kiyoe Kurahashi, Sumiko Yoshida, Takeshi Harada, Akio Kuroda, Toshiki Otoda, Tomoyuki Yuasa, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Phase angle and extracellular water-to-total body water ratio estimated by bioelectrical impedance analysis are associated with levels of hemoglobin and hematocrit in patients with diabetes., Heliyon, Vol.9, No.4, 2023. (Summary) PhA and ECW/TBW but not SMI were associated with levels of Hgb and Hct in patients with diabetes. Therefore, aberrant values of PhA and ECW/TBW suggest a risk of anemia in diabetic patients. (Tokushima University Institutional Repository) ● Metadata: 118251 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.heliyon.2023.e14724 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37057050 ● Search Scopus @ Elsevier (PMID): 37057050 ● Search Scopus @ Elsevier (DOI): 10.1016/j.heliyon.2023.e14724 (Tokushima University Institutional Repository: 118251, DOI: 10.1016/j.heliyon.2023.e14724, PubMed: 37057050)
11.	Tomoyo Hara, Ryoko Uemoto, Akiko Sekine, Yukari Mitsui, Shiho Masuda, Hiroki Yamagami, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Yasumasa Ikeda, Itsuro Endo, Soichi Honda, Katsuhiko Yoshimoto, Akira Kondo, Toshiaki Tamaki, Toshio Matsumoto, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Plasma Heparin Cofactor II Activity Is Inversely Associated with Hepatic Fibrosis of Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus., Journal of Atherosclerosis and Thrombosis, 2022. (Summary) Plasma HCII activity was inversely associated with clinical hepatic fibrosis indices including FIB-4 index, NFS and APRI and with the prevalence of advanced hepatic fibrosis in patients with T2DM. The results suggest that HCII can serve as a novel biomarker for assessment of hepatic fibrosis of NAFLD in patients with T2DM. (Tokushima University Institutional Repository) ● Metadata: 118258 (Link to Publication Site) ● Publication site (DOI): 10.5551/jat.63752 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36244745 ● Search Scopus @ Elsevier (PMID): 36244745 ● Search Scopus @ Elsevier (DOI): 10.5551/jat.63752 (Tokushima University Institutional Repository: 118258, DOI: 10.5551/jat.63752, PubMed: 36244745)
12.	Asami Okada, Misuzu Yamada-Yamashita, Yukari Tominaga, Kyoka Jo, Hiroyasu Mori, Reiko Suzuki, Masashi Ishizu, Motoyuki Tamaki, Yuko Akehi, Yuichi Takashi, Daisuke Koga, Eisuke Shimokita, Fuminori Tanihara, Kiyoe Kurahashi, Sumiko Yoshida, Yukari Mitsui, Shiho Masuda, Itsuro Endo, Ken-ichi Aihara, Shoji Kagami, Masahiro Abe, Kevin Ferreri, Yoshio Fujitani, Munehide Matsuhisa and Akio Kuroda : Novel method utilizing bisulfite conversion with dual amplification-refractory mutation system polymerase chain reaction to detect circulating pancreatic β-cell cfDNA., Journal of Diabetes Investigation, Vol.13, No.7, 1140-1148, 2022. (Summary) We developed a novel method for detecting unmethylated insulin DNA in circulation that can be performed using a conventional real-time PCR system. This method would be useful for analyzing dynamic profiles of β-cells in human disease such as type 1 diabetes. (Tokushima University Institutional Repository) ● Metadata: 117206 (Link to Publication Site) ● Publication site (DOI): 10.1111/jdi.13806 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35396829 ● Search Scopus @ Elsevier (PMID): 35396829 ● Search Scopus @ Elsevier (DOI): 10.1111/jdi.13806 (Tokushima University Institutional Repository: 117206, DOI: 10.1111/jdi.13806, PubMed: 35396829)
13.	Yumi Kuwamura, Sumiko Yoshida, Kiyoe Kurahashi, Masuko Sumikawa, Hiromichi Yumoto, Hirokazu Uemura and Munehide Matsuhisa : Effectiveness of a Diabetes Oral Nursing Program Including a Modified Diabetes Oral Health Assessment Tool for Nurses (M-DiOHAT©): A 12-Month Follow-Up Intervention Study, The Journal of Medical Investigation : JMI, Vol.69, No.1,2, 86-96, 2022. (Summary) This study aimed to evaluate the effectiveness of a diabetes oral nursing intervention program for individuals with diabetes. Fifty-six participants with diabetes underwent a diabetes oral nursing intervention program. The program's effect was evaluated through questionnaires and small interviews. The modified diabetes oral health assessment tool (M-DiOHAT©) was used to assess and educate four factors;oral conditions, behaviors, perceptions and knowledge about diabetes and periodontal disease, and health information-sharing, among participants at baseline, 3, 6, and 12 months later. Primary outcomes included changes in the M-DiOHAT© total scores. Secondary outcomes included scores on the motivation stage of changes in oral health behaviors' scales, dental visits, number of present teeth, hemoglobin A1c (HbA1c), and participants' comments. The M-DiOHAT© total score and the motivation stage score significantly improved with the narrative comment of "being motivated to practice oral health behaviors" between the baseline and 12 months later. Eight participants visited the dentist, whereas no differences were observed in the number of present teeth or HbA1c. This program improved participants' M-DiOHAT© total score, motivation stage score, and dental visits. These results suggest the program improved oral health perceptions and behaviors among individuals with diabetes. J. Med. Invest. 69 : 86-96, February, 2022. (Keyword) diabetes mellitus / nursing intervention / oral health behaviors / perception (Tokushima University Institutional Repository) ● Metadata: 117017 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.69.86 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35466152 ● Search Scopus @ Elsevier (PMID): 35466152 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.69.86 (Tokushima University Institutional Repository: 117017, DOI: 10.2152/jmi.69.86, PubMed: 35466152)
14.	Yukari Mitsui, Akio Kuroda, Masashi Ishizu, Hiroyasu Mori, Kiyoe Kurahashi, Takeshi Kondo, Sumiko Yoshida, Yuko Akehi, Ken-ichi Aihara, Itsuro Endo, Masahiro Abe and Munehide Matsuhisa : Basal insulin requirement in patients with type 1 diabetes depends on the age and body mass index., Journal of Diabetes Investigation, Vol.13, No.2, 292-298, 2022. (Summary) T (Tokushima University Institutional Repository) ● Metadata: 116546 (Link to Publication Site) ● Publication site (DOI): 10.1111/jdi.13547 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33740836 ● Search Scopus @ Elsevier (PMID): 33740836 ● Search Scopus @ Elsevier (DOI): 10.1111/jdi.13547 (Tokushima University Institutional Repository: 116546, DOI: 10.1111/jdi.13547, PubMed: 33740836)
15.	Masato Miyake, Mitsuaki Sobajima, Kiyoe Kurahashi, Akira Shigenaga, Masaya Denda, Akira Otaka, Tomohide Saio, Naoki Sakane, Hidetaka Kosako and Seiichi Oyadomari : Identification of an endoplasmic reticulum proteostasis modulator that enhances insulin production in pancreatic β cells., Cell Chemical Biology, Vol.29, No.6, 996-1009.e9, 2022. (Summary) Perturbation of endoplasmic reticulum (ER) proteostasis is associated with impairment of cellular function in diverse diseases, especially the function of pancreatic β cells in type 2 diabetes. Restoration of ER proteostasis by small molecules shows therapeutic promise for type 2 diabetes. Here, using cell-based screening, we report identification of a chemical chaperone-like small molecule, KM04794, that alleviates ER stress. KM04794 prevented protein aggregation and cell death caused by ER stressors and a mutant insulin protein. We also found that this compound increased intracellular and secreted insulin levels in pancreatic β cells. Chemical biology and biochemical approaches revealed that the compound accumulated in the ER and interacted directly with the ER molecular chaperone BiP. Our data show that this corrector of ER proteostasis can enhance insulin storage and pancreatic β cell function. (Keyword) Diabetes Mellitus, Type 2 / Endoplasmic Reticulum / Endoplasmic Reticulum Stress / Humans / Insulin / Insulin-Secreting Cells / Proteostasis / Unfolded Protein Response (Tokushima University Institutional Repository) ● Metadata: 116761 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.chembiol.2022.01.002 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35143772 ● Search Scopus @ Elsevier (PMID): 35143772 ● Search Scopus @ Elsevier (DOI): 10.1016/j.chembiol.2022.01.002 (Tokushima University Institutional Repository: 116761, DOI: 10.1016/j.chembiol.2022.01.002, PubMed: 35143772)
16.	Yukari Mitsui, Yuto Iizuka, Tomoaki Tanaka, Tomoyo Hara, Shiho Masuda, Yukiyo Ohnishi, Mai Kanai, Kiyoe Kurahashi, Sumiko Yoshida, Takeshi Kondo, Toshiko Kanezaki, Yasumi Shintani, Hiroki Yamagami, Hiroyuki Yamaguchi, Yuichi Fujinaka, Kana Morimoto, Atsuhisa Shirakami, Ken-ichi Aihara, Seiji Fukumoto, Masahiro Abe and Itsuro Endo : An attempt to create a treatment algorithm of central adrenal insufficiency using CRH test, DHEA-S and clinical evaluation., The Journal of Medical Investigation : JMI, Vol.69, No.3.4, 287-293, 2022. (Summary) Objective : To examine diagnostic performance of corticotropin-releasing hormone (CRH) test combined with baseline dehydroepiandrosterone sulfate (DHEA-S) in patients with a suspect of central adrenal insufficiency. Methods : Patients (n=215) requiring daily or intermittent hydrocortisone replacement, or no replacement were retrospectively checked with their peak cortisol after CRH test and baseline DHEA-S. Results : None of 106 patients with the peak cortisol · 17.5 g /L after CRH test required replacement, and all 64 patients with the peak cortisol < 10.0 g /L required daily replacement. Among 8 patients with 10.0 g /L the peak cortisol < 17.5 g /L and baseline DHEA-S below the reference range, 6 patients required daily replacement and 1 patient was under intermittent replacement. Among 37 patients with 10.0 g /L the peak cortisol < 17.5 g /L and baseline DHEA-S within the reference range, 10 and 6 patients were under intermittent and daily replacement, respectively. Conclusions : No patients with the peak cortisol · 17.5 g /L required hydrocortisone replacement, and all patients with the peak cortisol below 10.0 g /L required daily replacement. Careful clinical evaluation was required to determine requirement for replacement in patients with 10.0 g /L the peak cortisol < 17.5 g /L even in combination with baseline DHEA-S. J. Med. Invest. 69 : 287-293, August, 2022. (Keyword) Adrenal Insufficiency / Adrenocorticotropic Hormone / Algorithms / Corticotropin-Releasing Hormone / Dehydroepiandrosterone Sulfate / Humans / Hydrocortisone / Retrospective Studies (Tokushima University Institutional Repository) ● Metadata: 117738 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.69.287 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36244782 ● CiNii @ National Institute of Informatics (CRID): 1390575263318485248 ● Summary page in Scopus @ Elsevier: 2-s2.0-85139886801 (Tokushima University Institutional Repository: 117738, DOI: 10.2152/jmi.69.287, PubMed: 36244782, CiNii: 1390575263318485248, Elsevier: Scopus)
17.	Asami Okada, Misuzu Yamada, Hiroyasu Mori, 明比祐子, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa and Akio Kuroda : 循環血中遊離 DNA を用いた膵β細胞傷害の新規検出法の確立, Shikoku Acta Medica, Vol.77, No.5,6, 249-254, 2021. (Summary) In people with type1 diabetes(T1D), biomarkers that can sensitively and quantitatively evaluate injury of pancreatic beta cell are required in order to predict the onset of the disease at an early stage and to provide interventions to prevent the progression of the disease. We developed a new method for quantifying pancreatic beta cell-derived insulin DNA in circulation that combines bisulfite conversion and Amplification Refractory Mutation System(ARMS)PCR, which can be performed using a conventional real-time PCR system. We applied this method to T1D patients and healthy adults, both could be detected in about 30% of cases. The results in healthy adults indicate that this method may have sensitivity to detect the turnover of pancreatic beta cells at physiological conditions. In post-onset T1D patients, there were many negatives because the amount of residual pancreatic beta cells was extremely small. However, in some cases with a short duration of the disease, pancreatic beta cell-derived insulin DNA was detected in negative correlation between the duration of the disease, that suggested the residual pancreatic beta cells continue to be slowly destroyed. It was demonstrated that the time course of pathophysiology in T1D could be understood using this method. (Keyword) insulin / DNA methylation / RT-PCR / Type1 diabetes / cell-free DNA (Tokushima University Institutional Repository) ● Metadata: 117138 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520573657290659200 (Tokushima University Institutional Repository: 117138, CiNii: 1520573657290659200)
18.	木村蘭子, Kiyoe Kurahashi, 細木美苗, 辻誠士郎, 三井由加里, Sumiko Yoshida, 明比祐子, Itsuro Endo, Seiji Fukumoto and Masahiro Abe : 繰り返す脆弱性骨折を契機に発見されたクッシング症候群の一例, Shikoku Acta Medica, Vol.77, No.5-6, 269-274, 2021. (Summary) A 38-year-old woman had suffered from an avulsion fracture of the left cuboid bone, a rib fracture, a fatigue fracture of the left second metatarsal bone and a pubic fracture within the last 4 years. She also realized that her face was getting rounded and became aware of edema on extremities. She had repeated fragile fractures before menopause and was referred to our department on suspicion of secondary osteoporosis. The patients showed physical signs of moon face, central obesity, and abdominal violaceous striae. Cushing's syndrome was suspected, therefore confirmatory studies were performed. Circadian variation of cortisol : serum cortisol19．3μg/dL(at7:00), 21．4μg/dL(at23:00), urinary free cortisol :247．4μg/24h, ACTH :2．5pg/mL. Low-dose(1mg) dexamethasone did not suppress cortisol level(18．9μg/dL). Based on these findings, we diagnosed as Cushing's syndrome and glucocorticoid excess seemed to be the cause of secondary osteoporosis. Abdominal CT identified a 2．7 cm tumor in the left adrenal gland, and in-phase T1‐weighted MRI showed decreased signal compared to out-phase, suggesting an adrenocortical adenoma. She underwent laparoscopic left adrenalectomy. Postoperative fasting serum cortisol decreased to2．2 μg/dL, and glucocorticoid replacement therapy was started. It is necessary to find out any secondary causes for premenopausal women with fragility fractures. It is well known that endocrine disorders including Cushing's syndrome are the most frequent associated diseases in patients with premenopausal osteoporosis. Cushing's syndrome should be considered as a causative disease in premenopausal women with osteoporosis. (Keyword) Cushing syndrome / fragility fracture / Premenopausal woman (Tokushima University Institutional Repository) ● Metadata: 116832 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520855132277098624 (Tokushima University Institutional Repository: 116832, CiNii: 1520855132277098624)
19.	吉川紘平, 金子遥祐, 辻誠士郎, 河田沙紀, 川原綾香, 森建介, 遠藤ふうり, Tomoyo Hara, Kiyoe Kurahashi, Sumiko Yoshida, Akio Kuroda, 明比祐子, Itsuro Endo, Makoto Funaki, Seiji Fukumoto, Masahiro Abe and Munehide Matsuhisa : TIA様症状を契機に診断されたインスリノーマの1例, Shikoku Acta Medica, Vol.77, No.5-6, 275-280, 2021. (Summary) We report the case of a67-year-old woman who had symptoms suggestive of a transient ischemic attack(TIA), such as lightheadedness and transient visual changes before meals for 4 months. She experienced altered consciousness before lunch and was taken to the emergency room2weeks ago. She had repeated hypoglycemia with a blood glucose level of 31 mg/dL. Insulin secretion was not suppressed, with an immunoreactive insulin level of 14．0 μU/mL and connecting peptide immunoreactivity of 1．83 ng/mL for occasional blood glucose levels of 49 mg/dL. Dynamic CT revealed a 17‐mm mass enhanced during the arterial phase in the pancreatic uncinate process, suggestive of a pancreatic neuroendocrine tumor. A selective arterial secretagogue(calcium)injection test revealed the localization of insulinoma in the head of the pancreas. Therefore, pancreatoduodenectomy was performed. Hyperglycemia occurred after the surgery, and it was judged that the insulinoma was resected. This case showed TIA-like symptoms without signs of sympathetic overdrive associated with hypoglycemia. Thus, the diagnosis was delayed. Insulinoma may present with symptoms of neuroglycopenia but not autonomic activity due to hypoglycemia. Insulinoma should be distinguished in patients with unknown neurological symptoms since neuroglycopenia caused by insulinoma is diverse. (Keyword) Insulinoma / Hypoglycemia / Neuroglycopenia / Transient ischemic attack (Tokushima University Institutional Repository) ● Metadata: 116831 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520292182331094144 (Tokushima University Institutional Repository: 116831, CiNii: 1520292182331094144)
20.	川原綾香, Kiyoe Kurahashi, 工藤千晶, 鎌田基夢, Shinsuke Katoh, Yukiko Tomioka, 辻本賀美, 安井沙耶, 遠藤ふうり, 桝田志保, 三井由加里, Sumiko Yoshida, Ken-ichi Aihara, Itsuro Endo, Seiji Fukumoto, Munehide Matsuhisa and Masahiro Abe : 歩行不能だったが，多職種の高度な連携と患者特性に配慮したケアにより自宅生活可能となった高度肥満症の一例, Shikoku Acta Medica, Vol.76, No.5-6, 317-322, 2021. (Summary) A 48-year-old man who weighed 216 kg was significantly overweight with a body mass index (BMI)of 75．6kg/m2, and was unable to walk due to disuse syndrome. Because of the psychological and social problems in the background, a psychological examination was performed and the staff took time to build a trusting relationship with the patient, taking into account his characteristics. With diet and rehabilitation, he was able to lose weight to 124kg and BMI 43．9kg/m2 over 600 days, and was able to walk with assistive devices and defecate by himself. The patient was discharged from our hospital after a series of multidisciplinary meetings with medical, nursing, welfare, and governmental agencies to create an environment for home recuperation. The reasons for the improvement to enable him to be discharged from the hospital were due to the multi-disciplinary meetings among the staff inside and outside the hospital, information sharing and advanced coordination, and smooth communication with the patient by taking into account his characteristics from a psychological standpoint. (Keyword) Sever obesity / disuse syndrome / Patient-specific care / Multidisciplinary team (Tokushima University Institutional Repository) ● Metadata: 115801 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050583790041627392 (Tokushima University Institutional Repository: 115801, CiNii: 1050583790041627392)
21.	Tomoyo Hara, Ryoko Uemoto, Akiko Sekine, Yukari Mitsui, Shiho Masuda, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Yasumasa Ikeda, Itsuro Endo, Soichi Honda, Katsuhiko Yoshimoto, Akira Kondo, Toshiaki Tamaki, Toshio Matsumoto, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Plasma Heparin Cofactor II Activity Is Inversely Associated with Albuminuria and Its Annual Deterioration in Patients with Diabetes., Journal of Diabetes Investigation, 2021. (Summary) The plasma HCII activity was inversely and specifically associated with glomerular injury in patients with diabetes. The results suggest that HCII can serve as a novel predictive factor for early-stage DKD development, as represented by albuminuria. (Tokushima University Institutional Repository) ● Metadata: 116545 (Link to Publication Site) ● Publication site (DOI): 10.1111/jdi.13602 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34043882 ● Search Scopus @ Elsevier (PMID): 34043882 ● Search Scopus @ Elsevier (DOI): 10.1111/jdi.13602 (Tokushima University Institutional Repository: 116545, DOI: 10.1111/jdi.13602, PubMed: 34043882)
22.	桝田志保, Sumiko Yoshida, 工藤千晶, 辻本賀美, 安井沙耶, 遠藤ふうり, 三井由加里, Kiyoe Kurahashi, Itsuro Endo, 轟貴史 and Masahiro Abe : Delayed diagnosis of thyroid storm in an elderly patient: A case report, Japanese Journal of Geriatrics, Vol.58, No.1, 158-163, 2021. (Summary) <p>A 70-year-old woman was hospitalized for diarrhea, vomiting, loss of appetite, fatigue, and dyspnea on exertion for the past 3 weeks and treated with intravenous fluid for dehydration. She was receiving prednisolone for polymyositis. She did not have a history of thyroid disease. On day 4 of hospitalization, the patient was diagnosed with congestive heart failure and tachycardiac atrial fibrillation, and treatment with a diuretic agent was initiated. On day 7 of hospitalization, a clinical laboratory evaluation revealed that the level of free thyroxine was 9.95 ng/dL, free triiodothyronine was >30 pg/mL, and thyroid-stimulating hormone was <0.01 μU/mL, and the patient was initially diagnosed with thyrotoxicosis because of Graves' disease. She showed restlessness and had a fever of 39 °C, tachycardia of ≥140 beats/min, pulmonary edema, and frequent diarrhea, all of which were consistent with the symptoms of thyroid storm. Her general condition gradually improved with comprehensive treatment of thyroid storm comprising thiamazole, potassium iodide, hydrocortisone, and landiolol. A reassessment revealed that the patient had already had thyrotoxicosis and thyroid storm on admission. Thyroid storm is a potentially fatal disease that must be urgently addressed; however, its symptoms are difficult to distinguish from those caused by other diseases. Furthermore, elderly individuals may not exhibit typical symptoms of thyroid storm, so the diagnosis is difficult. In this case, the diagnosis was delayed because of the absence of typical symptoms of thyroid storm and the influence of a pre-existing medical condition and medication.</p> (Keyword) Thyroid storm / Graves' disease / Atrial fibrillation / Heart failure / Takotsubo cardiomyopathy (Link to Publication Site) ● Publication site (DOI): 10.3143/geriatrics.58.158 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390568772520282112 ● Search Scopus @ Elsevier (DOI): 10.3143/geriatrics.58.158 (DOI: 10.3143/geriatrics.58.158, CiNii: 1390568772520282112)
23.	Akira Takashima, Shusuke Yagi, Koji Yamaguchi, Kiyoe Kurahashi, Yuko Kojima, Robert Zheng, Takayuki Ise, Kenya Kusunose, Sumiko Yoshida, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Ken-ichi Aihara, Masashi Akaike and Masataka Sata : Congenital Hypogonadotropic Hypogonadism with Early-Onset Coronary Artery Disease., The Journal of Medical Investigation : JMI, Vol.68, No.1.2, 189-191, 2021. (Summary) The patient with congenital hypogonadotropic hypogonadism (HH) shows low serum levels of androgen, which is a group of sex hormones including testosterone, caused by the decreased gonadotropin release in the hypothalamus. Recent reports showed androgens exert protective effects against insulin resistance or atherosclerotic diseases, such as diabetes mellitus or coronary artery disease. However, whether the juvenile hypogonadism affects the diabetes or cardiovascular disease is unclear. We report a case of a middle-aged man with congenital HH who had severe coronary artery disease complicated with metabolic disorders. J. Med. Invest. 68 : 189-191, February, 2021. (Tokushima University Institutional Repository) ● Metadata: 116019 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.189 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33994469 ● Search Scopus @ Elsevier (PMID): 33994469 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.189 (Tokushima University Institutional Repository: 116019, DOI: 10.2152/jmi.68.189, PubMed: 33994469)
24.	岩坂麻衣子, Mio Yada, Yoshiaki Kubo and Kiyoe Kurahashi : 腹壁遠心性脂肪萎縮症の1例, Hifuka No Rinsho, Vol.62, No.13, 1929-1932, 2020. (Keyword) 腹壁遠心性脂肪萎縮症 / 成人 (Link to Publication Site) ● Publication site (DOI): 10.18888/hi.0000002309 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390568456343666560 ● Search Scopus @ Elsevier (DOI): 10.18888/hi.0000002309 (DOI: 10.18888/hi.0000002309, CiNii: 1390568456343666560)
25.	Yumi Kuwamura, Sumiko Yoshida, Kiyoe Kurahashi, 澄川真珠子, Eijiro Sakamoto, Akio Kuroda, Ken-ichi Aihara, Makoto Funaki, Hiromichi Yumoto, Hirokazu Uemura, 岡本美鈴, 大和光, Munehide Matsuhisa, Itsuro Endo and Sachi Kishida : 糖尿病患者の口腔保健行動アセスメントツールを用いた看護支援プログラムの評価, Journal of the The Japan Diabetes Society, Vol.63, No.Supplement, S117, 2020. (Keyword) diabetes mellitus / oral health behaviors / assessment / 看護支援
26.	Yumi Kuwamura, Sumiko Yoshida, Kiyoe Kurahashi, Masuko Sumikawa, Eijiro Sakamoto, Ken-ichi Aihara, Hiromichi Yumoto, Akio Kuroda, Itsuro Endo, Toshiyuki Yasui and Sachi Kishida : Modified diabetes oral health assessment tool (M-DiOHAT©) for nurses and their association with efficacy beliefs and outcome expectancies in patients with diabetes, JNI : The Journal of Nursing Investigation, Vol.18, No.1, 13-26, 2020. (Keyword) diabetes mellitus / assessment / nursing / oral health behaviors (Tokushima University Institutional Repository) ● Metadata: 114058 (Link to Publication Site) ● Publication site (DOI): 10.32273/jni.JNI_018_013 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.32273/jni.JNI_018_013 (Tokushima University Institutional Repository: 114058, DOI: 10.32273/jni.JNI_018_013)
27.	Kenji Nishimura, Taichi Murakami, Toshihiro Sakurai, Masashi Miyoshi, Kiyoe Kurahashi, Seiji Kishi, Masanori Tamaki, Tatsuya Tominaga, Sumiko Yoshida, Kojiro Nagai, Hideharu Abe, Shu-Ping Hui, Kazuhiko Kotani and Toshio Doi : Circulating Apolipoprotein L1 is associated with insulin resistance-induced abnormal lipid metabolism., Scientific Reports, Vol.9, No.1, 14869, 2019. (Summary) Circulating ApolipoproteinL1 (ApoL1) is a component of pre-β-high-density lipoprotein (HDL), however little is known about the relationship of ApoL1 with cardiometabolic factors. Considering previous studies reporting the correlation of ApoL1 to triglyceride, we have hypothesized that ApoL1 associates with insulin-related metabolism. The current study examined their associations in 126 non-diabetic subjects and 36 patients with type 2 diabetes (T2DM). Non-diabetic subjects demonstrated triglyceride (standardized coefficients [s.c.] = 0.204, p < 0.05), body mass index (s.c. =0.232, p < 0.05) and HDL cholesterol (s.c. = -0.203, p < 0.05) as independent determinant of ApoL1 levels, and the significant elevation of ApoL1 in metabolic syndrome. Lipoprotein fractionation analysis revealed the predominant distribution of ApoL1 in large HDL fraction, and the significant increase of ApoL1 in large LDL fraction in high ApoL1 samples with insulin resistance. In T2DM, ApoL1 was higher in T2DM with metabolic syndrome, however ApoL1 was lower with β cell dysfunction. Insulin significantly promotes ApoL1 synthesis and secretion in HepG2 cells. In conclusion, circulating ApoL1 may be associated with abnormal HDL metabolism in insulin resistant status. This may suggest a regulation of insulin signal on the ApoL1 level, leading to offer a novel insight to the ApoL1 biology. (Tokushima University Institutional Repository) ● Metadata: 114663 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-019-51367-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31619724 ● Search Scopus @ Elsevier (PMID): 31619724 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-019-51367-7 (Tokushima University Institutional Repository: 114663, DOI: 10.1038/s41598-019-51367-7, PubMed: 31619724)
28.	Hiroya Matsuda, Kiyoe Kurahashi, Furi Endo, Shiho Masuda, Yukari Mitsui, Sumiko Yoshida, Yuko Akehi, Itsuro Endo and Seiji Fukumoto : A case of isolated ACTH deficiency that required 6 months for the diagnosis from onset., Shikoku Acta Medica, Vol.75, No.1, 2, 69-74, 2019. (Summary) A 53-year-old man noticed anorexia, nausea, and arthralgia of the upper limbs in April, 201X. Since these symptoms persisted, he visited general hospital and clinic and was examined for blood chemistry, ECG, echocardiography and so on. However, he did not get a definitive diagnosis and was followed up with drip infusion of saline. The symptoms did not subside and fatigue and syncope with hypotension developed. Furthermore, he also suffered weight loss of 10 kg in few months and was referred to our hospital for more detailed examinations in October, 201X. Upon the initial examination, all his symptoms matched those of adrenal insufficiency and notable decreases of both plasma ACTH and serum cortisol level were observed. Prompt glucocorticoid supplementation improved his symptoms and the abnormal laboratory data immediately. He was diagnosed adrenal insufficiency due to isolated ACTH deficiency from the results of CRH loading test and insulin tolerance test. Since most of the symptoms and laboratory findings are non-specific, diagnosis of adrenal insufficiency is often delayed. However, adrenal insufficiency could worsen when the patient is under stress (e.g. infection) and often be life-threatening. Glucocorticoid replacement therapy should be initiated as soon as the diagnosis is confirmed. Furthermore, educating patients and his families plays a very important role in the management of chronic adrenal insufficiency, in particular to the prevention of adrenal crisis. (Keyword) isolated ACTH deficiency / adrenal insufficiency / anorexia / nausea / arthralgia (Tokushima University Institutional Repository) ● Metadata: 113765 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050302172852907520 (Tokushima University Institutional Repository: 113765, CiNii: 1050302172852907520)
29.	Dong Bingzi, Itsuro Endo, Ohnishi Yukoyo, Mitsui Yukari, Kiyoe Kurahashi, Mai Kanai, Masahiro Hiasa, Jumpei Teramachi, Hirofumi Tenshin, Seiji Fukumoto, Masahiro Abe and Toshio Matsumoto : Persistent Activation of Calcium-Sensing Receptor Suppresses Bone Turnover, Increases Microcracks, and Decreases Bone Strength., JBMR Plus, Vol.3, No.7, e10182, 2019. (Summary) Activating mutations of calcium-sensing receptor (CaSR) cause autosomal dominant hypocalcemia type 1 (ADH1). Patients with ADH1 exhibit similar features to patients with hypoparathyroidism, including reduced serum parathyroid hormone (PTH) and Ca with low bone turnover. Although persistent suppression of bone turnover may increase bone fragility, bone strength in ADH1 patients has been unclear. We created knock-in mice harboring the A843E activating mutation of CaSR, mimicking severe features of ADH1 patients. The severe form of ADH1 model mice showed smaller body and bone size with lower bone mineral density (BMD) and cortical area of the femur compared with age-matched wild-type (WT) mice. Bone strength in the femur was lower in ADH1 mice even after correction by bone geometry and/or BMD. Microcracks were markedly increased in ADH1 mice, but were rarely detected in WT mice. There was a negative correlation between bone strength corrected by bone geometry and/or BMD and microcrack number or density in ADH1 and WT mice. Among ADH1 mice, negative correlation was still observed between bone strength and microcrack number or density. Microcracks increased with age in ADH1 mice, and were negatively correlated with bone strength. Treatment with PTH(1-34) or a calcilytic, JTT-305, increased bone turnover, reduced microcracks, and increased bone strength to similar levels to those in WT mice. The increase in microcracks was associated with a reduction in bone strength in ADH1 mice, and aging aggravates these changes. These results demonstrate that activating mutation of CaSR causes reduction in PTH secretion with suppressed bone turnover, that reduced bone turnover is associated with an age-dependent increase in microcracks with a reduction in bone strength, and that both PTH(1-34) and calcilytic ameliorate all these changes in bone turnover and strength. It is suggested that fracture susceptibility may be increased in severe types of ADH1 patients especially in the elderly. © 2019 The Authors. published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research. (Link to Publication Site) ● Publication site (DOI): 10.1002/jbm4.10182 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31372589 ● Search Scopus @ Elsevier (PMID): 31372589 ● Search Scopus @ Elsevier (DOI): 10.1002/jbm4.10182 (DOI: 10.1002/jbm4.10182, PubMed: 31372589)
30.	Hiroyasu Mori, Akio Kuroda, Masashi Ishizu, Mami Ohishi, Yuichi Takashi, Yinhua Otsuka, Satoshi Taniguchi, Motoyuki Tamaki, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki, Yuko Akehi and Munehide Matsuhisa : Association of accumulated advanced glycation end-products with a high prevalence of sarcopenia and dynapenia in patients with type 2 diabetes., Journal of Diabetes Investigation, 2019. (Summary) Advanced glycation end-products (AGEs), which are a major cause of diabetic vascular complications, accumulate in various tissues under chronic hyperglycemic conditions, as well as with aging in patients with diabetes. The loss of muscle mass and strength, so-called sarcopenia and dynapenia, has recently been recognized as a diabetic complication. However, the influence of accumulated AGEs on muscle mass and strength remains unclear. The present study aimed to evaluate the association of sarcopenia and dynapenia with accumulated AGEs in patients with type 2 diabetes. We recruited 166 patients with type 2 diabetes aged 30 years (mean age 63.2 ± 12.3 years; body mass index 26.3 ± 4.9 kg/m ; glycated hemoglobin 7.1 ± 1.1%). Skin autofluorescence as a marker of AGEs, limb skeletal muscle mass index, grip strength, knee extension strength and gait speed were assessed. Sarcopenia and dynapenia were observed in 7.2 and 13.9% of participants, respectively. Skin autofluorescence was significantly higher in patients with sarcopenia and dynapenia. Skin autofluorescence was the independent determinant for skeletal muscle mass index, grip strength, knee extension strength, sarcopenia and dynapenia. Accumulated AGEs could contribute to reduced muscle mass and strength, leading to sarcopenia and dynapenia in patients with type 2 diabetes. (Tokushima University Institutional Repository) ● Metadata: 114022 (Link to Publication Site) ● Publication site (DOI): 10.1111/jdi.13014 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30677242 ● Search Scopus @ Elsevier (PMID): 30677242 ● Search Scopus @ Elsevier (DOI): 10.1111/jdi.13014 (Tokushima University Institutional Repository: 114022, DOI: 10.1111/jdi.13014, PubMed: 30677242)
31.	Ariunzaya Bat-Erdene, Shingen Nakamura, Asuka Oda, Masami Iwasa, Jumpei Teramachi, Mohannad Ashtar, Takeshi Harada, Hirokazu Miki, Hirofumi Tenshin, Masahiro Hiasa, Shiroh Fujii, Kimiko Sogabe, Masahiro Oura, Kengo Udaka, Kumiko Kagawa, Sumiko Yoshida, Ken-ichi Aihara, Kiyoe Kurahashi, Itsuro Endo and Masahiro Abe : Class 1 HDAC and HDAC6 inhibition inversely regulates CD38 induction in myeloma cells via interferon-α and ATRA., British Journal of Haematology, 2018. (Tokushima University Institutional Repository) ● Metadata: 113393 (Link to Publication Site) ● Publication site (DOI): 10.1111/bjh.15673 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30474853 ● Summary page in Scopus @ Elsevier: 2-s2.0-85057280798 (Tokushima University Institutional Repository: 113393, DOI: 10.1111/bjh.15673, PubMed: 30474853, Elsevier: Scopus)
32.	Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Takeshi Harada, Shingen Nakamura, Ryota Amachi, Hirofumi Tenshin, Masami Iwasa, Shiroh Fujii, Kumiko Kagawa, Hirokazu Miki, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe : Pim-2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma., British Journal of Haematology, Vol.180, No.4, 581-585, 2018. (Tokushima University Institutional Repository) ● Metadata: 112935 (Link to Publication Site) ● Publication site (DOI): 10.1111/bjh.14388 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27748523 ● Search Scopus @ Elsevier (PMID): 27748523 ● Search Scopus @ Elsevier (DOI): 10.1111/bjh.14388 (Tokushima University Institutional Repository: 112935, DOI: 10.1111/bjh.14388, PubMed: 27748523)
33.	Shiroh Fujii, Shingen Nakamura, Asuka Oda, Hirokazu Miki, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Ariunzaya Bat-Erdene, Yusaku Maeda, Masahiro Oura, Mamiko Takahashi, Masami Iwasa, Itsuro Endo, Sumiko Yoshida, Ken-ichi Aihara, Kiyoe Kurahashi, Takeshi Harada, Kumiko Kagawa, Michiyasu Nakao, Shigeki Sano and Masahiro Abe : Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity., British Journal of Haematology, Vol.180, No.2, 246-258, 2018. (Summary) Proviral Integrations of Moloney virus 2 (PIM2) is overexpressed in multiple myeloma (MM) cells, and regarded as an important therapeutic target. Here, we aimed to validate the therapeutic efficacy of different types of PIM inhibitors against MM cells for their possible clinical application. Intriguingly, the thiazolidine-2,4-dione-family compounds SMI-16a and SMI-4a reduced PIM2 protein levels and impaired MM cell survival preferentially in acidic conditions, in contrast to other types of PIM inhibitors, including AZD1208, CX-6258 and PIM447. SMI-16a also suppressed the drug efflux function of breast cancer resistance protein, minimized the sizes of side populations and reduced in vitro colony-forming capacity and in vivo tumourigenic activity in MM cells, suggesting impairment of their clonogenic capacity. PIM2 is known to be subject to ubiquitination-independent proteasomal degradation. Consistent with this, the proteasome inhibitors bortezomib and carfilzomib increased PIM2 protein levels in MM cells without affecting its mRNA levels. However, SMI-16a mitigated the PIM2 protein increase and cooperatively enhanced anti-MM effects in combination with carfilzomib. Collectively, the thiazolidine-2,4-dione-family compounds SMI-16a and SMI-4a uniquely reduce PIM2 protein in MM cells, which may contribute to their profound efficacy in addition to their immediate kinase inhibition. Their combination with proteasome inhibitors is envisioned. (Keyword) Animals / Antineoplastic Agents / Cell Line, Tumor / Cell Survival / Cell Transformation, Neoplastic / Disease Models, Animal / Humans / Hydrogen-Ion Concentration / Mice / Multiple Myeloma / Proteasome Inhibitors / Protein-Serine-Threonine Kinases / Proteolysis / Proto-Oncogene Proteins / Thiazolidinediones (Tokushima University Institutional Repository) ● Metadata: 112752 (Link to Publication Site) ● Publication site (DOI): 10.1111/bjh.15033 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29327347 ● Summary page in Scopus @ Elsevier: 2-s2.0-85040344893 (Tokushima University Institutional Repository: 112752, DOI: 10.1111/bjh.15033, PubMed: 29327347, Elsevier: Scopus)
34.	Hirokazu Miki, Shingen Nakamura, Asuka Oda, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Ariunzaya Bat-Erdene, Yusaku Maeda, Masahiro Oura, Mamiko Takahashi, Masami Iwasa, Takeshi Harada, Shiroh Fujii, Kiyoe Kurahashi, Sumiko Yoshida, Kumiko Kagawa, Itsuro Endo, Aihara Kenichi, Mariko Ikuo, Kouji Itou, Koichiro Hayashi, Michihiro Nakamura and Masahiro Abe : Effective impairment of myeloma cells and their progenitors by hyperthermia., Oncotarget, Vol.9, No.12, 10307-10316, 2017. (Summary) Multiple myeloma (MM) remains incurable, and MM-initiating cells or MM progenitors are considered to contribute to disease relapse through their drug-resistant nature. In order to improve the therapeutic efficacy for MM, we recently developed novel superparamagnetic nanoparticles which selectively accumulate in MM tumors and extirpate them by heat generated with magnetic resonance. We here aimed to clarify the therapeutic effects on MM cells and their progenitors by hyperthermia. Heat treatment at 43°C time-dependently induced MM cell death. The treatment upregulated endoplasmic reticulum (ER) stress mediators, ATF4 and CHOP, while reducing the protein levels of Pim-2, IRF4, c-Myc and Mcl-1. Combination with the proteasome inhibitor bortezomib further enhanced ER stress to potentiate MM cell death. The Pim inhibitor SMI-16a also enhanced the reduction of the Pim-2-driven survival factors, IRF4 and c-Myc, in combination with the heat treatment. The heat treatment almost completely eradicated "side population" fractions in RPMI8226 and KMS-11 cells and suppressed their clonogenic capacity as determined by colony formation and tumorigenic capacity in SCID mice. These results collectively demonstrated that hyperthermia is able to impair clonogenic drug-resistant fractions of MM cells and enhance their susceptibility to chemotherapeutic drugs. (Tokushima University Institutional Repository) ● Metadata: 113059 (Link to Publication Site) ● Publication site (DOI): 10.18632/oncotarget.23121 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29535808 ● Summary page in Scopus @ Elsevier: 2-s2.0-85041952629 (Tokushima University Institutional Repository: 113059, DOI: 10.18632/oncotarget.23121, PubMed: 29535808, Elsevier: Scopus)
35.	Shusuke Yagi, Ken-ichi Aihara, Takeshi Kondo, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Daiju Fukuda, Yutaka Nakaya, Kin-Ichiro Suwaki, Takashi Takeji, Toshihiro Wada, Masdan Hotimah Salim, Saori Hama, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Koji Yamaguchi, Takeshi Tobiume, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Munehide Matsuhisa, Michio Shimabukuro, Masashi Akaike and Masataka Sata : Predictors for the Treatment Effect of Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus., Advances in Therapy, Vol.35, No.1, 124-134, 2017. (Summary) Predictors for the effect of sodium glucose co-transporter 2 (SGLT2) inhibitors at lowering hemoglobin A1c (HbA1c) levels in type 2 diabetes mellitus patients remain unclear. We therefore aimed to elucidate these predictors in type 2 diabetes patients after 3 months of SGLT2 treatment. A total of 302 consecutive type 2 diabetes patients who had been treated with SGLT2 inhibitors as monotherapy or add-on therapy to existing antidiabetic treatments were enrolled retrospectively. After excluding 27 patients whose HbA1c levels could not be evaluated 3 months after treatment, the glucose-lowering effects of SGLT2 inhibitors were assessed in 275 patients by measuring HbA1c levels before and 3 months after treatment. The predictors for changes in HbA1c levels after 3 months of treatment were evaluated. SGLT2 inhibitor treatment for 3 months decreased HbA1c levels from 7.8 ± 1.2% to 7.4 ± 1.0% (p < 0.0001). A multiple regression analysis showed that the independent determinants for SGLT2 inhibitor treatment effect included decreased HbA1c levels after 1 month of treatment, high baseline HbA1c levels, and a high estimated glomerular filtration rate (eGFR). We show that type 2 diabetes patients who received the greatest glucose-lowering effect with SGLT2 inhibitor treatment were those with preserved renal function (high baseline eGFR) and high baseline HbA1c levels. Moreover, SGLT2 inhibitor treatment efficacy could be predicted by the patients' initial response to treatment. (Link to Publication Site) ● Publication site (DOI): 10.1007/s12325-017-0639-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29185199 ● Summary page in Scopus @ Elsevier: 2-s2.0-85035102977 (DOI: 10.1007/s12325-017-0639-z, PubMed: 29185199, Elsevier: Scopus)
36.	Hirofumi Tenshin, Jumpei Teramachi, Asuka Oda, Ryota Amachi, Masahiro Hiasa, Ariunzaya Bat-Erdene, Keiichiro Watanabe, Masami Iwasa, Takeshi Harada, Shiroh Fujii, Kumiko Kagawa, Kimiko Sogabe, Shingen Nakamura, Hirokazu Miki, Kiyoe Kurahashi, Sumiko Yoshida, Kenichi Aihara, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe : TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects., Blood Advances, Vol.1, No.24, 2124-2137, 2017. (Summary) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) agonists induce tumor-specific apoptosis indicating that they may be an attractive therapeutic strategy against cancers, including multiple myeloma (MM). Osteoclastogenesis is highly induced in MM, which in turn enhances MM growth, thereby forming a vicious cycle between MM tumor expansion and bone destruction. However, the effects of TRAIL on MM-enhanced osteoclastogenesis remain largely unknown. Here, we show that TRAIL induced apoptosis in MM cells, but not in osteoclasts (OCs), and that it rather facilitated receptor activator of NF-B ligand-induced osteoclastogenesis along with upregulation of cellular FLICE inhibitory protein (c-FLIP). TRAIL did not induce death-inducing signaling complex formation in OCs, but formed secondary complex (complex II) with the phosphorylation of transforming growth factor -activated kinase-1 (TAK1), and thus activated NF-B signaling. c-FLIP knockdown abolished complex II formation, thus permitting TRAIL induction of OC cell death. The TAK1 inhibitor LLZ1640-2 abrogated the TRAIL-induced c-FLIP upregulation and NF-B activation, and triggered TRAIL-induced caspase-8 activation and cell death in OCs. Interestingly, the TRAIL-induced caspase-8 activation caused enzymatic degradation of the transcription factor Sp1 to noticeably reduce c-FLIP expression, which further sensitized OCs to TRAIL-induced apoptosis. Furthermore, the TAK1 inhibition induced antiosteoclastogenic activity by TRAIL even in cocultures with MM cells while potentiating TRAIL's anti-MM effects. These results demonstrated that osteoclastic lineage cells use TRAIL for their differentiation and activation through tilting caspase-8-dependent apoptosis toward NF-B activation, and that TAK1 inhibition subverts TRAIL-mediated NF-B activation to resume TRAIL-induced apoptosis in OCs while further enhancing MM cell death in combination with TRAIL. (Tokushima University Institutional Repository) ● Metadata: 111724 (Link to Publication Site) ● Publication site (DOI): 10.1182/bloodadvances.2017008813 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29296860 ● Search Scopus @ Elsevier (PMID): 29296860 ● Search Scopus @ Elsevier (DOI): 10.1182/bloodadvances.2017008813 (Tokushima University Institutional Repository: 111724, DOI: 10.1182/bloodadvances.2017008813, PubMed: 29296860)
37.	Kiyoe Kurahashi, Itsuro Endo, Takeshi Kondo, Kana Morimoto, Sumiko Yoshida, Akio Kuroda, Ken-ichi Aihara, Munehide Matsuhisa, Kohhei Nakajima, Yoshifumi Mizobuchi, Shinji Nagahiro, Masahiro Abe and Seiji Fukumoto : Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review., Internal Medicine, Vol.56, No.18, 2455-2461, 2017. (Summary) Acromegaly is caused by excessive growth hormone secretion, usually from pituitary adenomas. Somoatostatin analogues are widely used as primary or adjunctive therapy in the management of acromegaly. In this report, we present a case with remarkable shrinkage of a tumor after relatively short-term octreotide long-acting release (LAR) administration. During the 30-month follow-up after starting octreotide LAR, there was no recurrence of acromegaly with remarkable shrinkage of the tumor on pituitary magnetic resonance imaging. A literature review of the predictors for tumor shrinkage after the administration of somatostatin analogues in patients with acromegaly is also discussed in relation to this case. (Tokushima University Institutional Repository) ● Metadata: 114396 (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.8223-16 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28824054 ● Summary page in Scopus @ Elsevier: 2-s2.0-85029653591 (Tokushima University Institutional Repository: 114396, DOI: 10.2169/internalmedicine.8223-16, PubMed: 28824054, Elsevier: Scopus)
38.	Kiyoe Kurahashi, Seika Inoue, Sumiko Yoshida, Yasumasa Ikeda, Kana Morimoto, Ryoko Uemoto, Kazue Ishikawa, Takeshi Kondo, Tomoyuki Yuasa, Itsuro Endo, Masato Miyake, Seiichi Oyadomari, Toshio Matsumoto, Masahiro Abe, Hiroshi Sakaue and Ken-ichi Aihara : The Role of Heparin Cofactor in the Regulation of Insulin Sensitivity and Maintenance of Glucose Homeostasis in Humans and Mice., Journal of Atherosclerosis and Thrombosis, 2017. (Summary) The present studies provide evidence to support the idea that HC plays an important role in the maintenance of glucose homeostasis by regulating insulin sensitivity in both humans and mice. Stimulators of HC production may serve as novel therapeutic tools for the treatment of type 2 diabetes. (Tokushima University Institutional Repository) ● Metadata: 110925 (Link to Publication Site) ● Publication site (DOI): 10.5551/jat.37739 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28502917 ● Search Scopus @ Elsevier (PMID): 28502917 ● Search Scopus @ Elsevier (DOI): 10.5551/jat.37739 (Tokushima University Institutional Repository: 110925, DOI: 10.5551/jat.37739, PubMed: 28502917)
39.	Takeshi Kondo, Itsuro Endo, Yukari Ooguro, Kana Morimoto, Kiyoe Kurahashi, Sumiko Yoshida, Akio Kuroda, Ken-ichi Aihara, Munehide Matsuhisa, Masahiro Abe and Seiji Fukumoto : Suppression of the Hypothalamic-pituitary-adrenal Axis by Maximum Androgen Blockade in a Patient with Prostate Cancer., Internal Medicine, Vol.55, No.24, 3623-3626, 2016. (Summary) A 78-year-old Japanese man showed suppression of the hypothalamic-pituitary-adrenal axis during maximum androgen blockade (MAB) therapy including chlormadinone acetate (CMA) for prostate cancer. After stopping the MAB therapy, both the basal ACTH level and the response to CRH recovered. While no reports have indicated that CMA suppresses the hypothalamic-pituitary-adrenal axis in patients with prostate cancer, CMA has been shown to inhibit this axis in animals. These observations suggest that we must monitor the hypothalamic-pituitary-adrenal axis in patients treated with CMA, especially under stressful conditions. (Keyword) Adrenal Glands / Adrenocorticotropic Hormone / Aged / Androgen Antagonists / Animals / Antineoplastic Agents / Chlormadinone Acetate / Corticotropin-Releasing Hormone / Diabetes Mellitus, Type 2 / Humans / Hypothalamo-Hypophyseal System / Male / Pituitary-Adrenal System / Prostatic Neoplasms / Treatment Outcome (Tokushima University Institutional Repository) ● Metadata: 114392 (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.55.7359 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27980263 ● Summary page in Scopus @ Elsevier: 2-s2.0-85007140325 (Tokushima University Institutional Repository: 114392, DOI: 10.2169/internalmedicine.55.7359, PubMed: 27980263, Elsevier: Scopus)
40.	Ryota Amachi, Masahiro Hiasa, Jumpei Teramachi, Takeshi Harada, Asuka Oda, Shingen Nakamura, Derek Hanson, Keiichiro Watanabe, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Masami Iwasa, Itsuro Endo, Takeshi Kondo, Sumiko Yoshida, Ken-ichi Aihara, Kiyoe Kurahashi, Yoshiaki Kuroda, Hideaki Horikawa, Eiji Tanaka, Masahiro Abe and Toshio Matsumoto : A vicious cycle between acid sensing and survival signaling in myeloma cells: acid-induced epigenetic alteration., Oncotarget, Vol.7, No.43, 70447-70461, 2016. (Summary) Myeloma (MM) cells and osteoclasts are mutually interacted to enhance MM growth while creating acidic bone lesions. Here, we explored acid sensing of MM cells and its role in MM cell response to acidic conditions. Acidic conditions activated the PI3K-Akt signaling in MM cells while upregulating the pH sensor transient receptor potential cation channel subfamily V member 1 (TRPV1) in a manner inhibitable by PI3K inhibition. The acid-activated PI3K-Akt signaling facilitated the nuclear localization of the transcription factor Sp1 to trigger the expression of its target genes, including TRPV1 and HDAC1. Consistently, histone deacetylation was enhanced in MM cells in acidic conditions, while repressing a wide variety of genes, including DR4. Indeed, acidic conditions deacetylated histone H3K9 in a DR4 gene promoter and curtailed DR4 expression in MM cells. However, inhibition of HDAC as well as either Sp1 or PI3K was able to restore DR4 expression in MM cells suppressed in acidic conditions. These results collectively demonstrate that acid activates the TRPV1-PI3K-Akt-Sp1 signaling in MM cells while inducing HDAC-mediated gene repression, and suggest that a positive feedback loop between acid sensing and the PI3K-Akt signaling is formed in MM cells, leading to MM cell response to acidic bone lesions. (Tokushima University Institutional Repository) ● Metadata: 113048 (Link to Publication Site) ● Publication site (DOI): 10.18632/oncotarget.11927 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27626482 ● Search Scopus @ Elsevier (PMID): 27626482 ● Search Scopus @ Elsevier (DOI): 10.18632/oncotarget.11927 (Tokushima University Institutional Repository: 113048, DOI: 10.18632/oncotarget.11927, PubMed: 27626482)
41.	Takeshi Kondo, Itsuro Endo, Ken-ichi Aihara, Ohnishi Yukiyo, Dong Bingzi, Oguro Yukari, Kiyoe Kurahashi, Sumiko Yoshida, Yuichi Fujinaka, Akio Kuroda, Munehide Matsuhisa, Seiji Fukumoto, Toshio Matsumoto and Masahiro Abe : Serum carboxy-terminal telopeptide of type I collagen levels are associated with carotid atherosclerosis in patients with cardiovascular risk factors., Endocrine Journal, Vol.63, No.4, 397-404, 2016. (Summary) Carboxy-terminal telopeptide of type I collagen (ICTP) is generated through matrix metalloproteinase (MMP)-dependent type I collagen digestion, and has been widely utilized as a biomarker for bone turnover. The fact that atherosclerotic lesions are rich in both type I collagen and MMP-producing macrophages led to the hypothesis that serum ICTP concentrations may serve as a non-invasive clinical biomarker for atherosclerosis. Therefore, the association of serum ICTP concentrations with the maximum intima-media thickness (IMT) of carotid arteries, a surrogate index of systemic atherosclerosis, or brachial-ankle pulse wave velocity (baPWV) in patients with atherosclerotic risk factors was evaluated. A total of 52 male and 65 female (mean age: 62.8 yrs) patients without renal failure, malignancies or bone diseases known to affect serum ICTP concentrations were recruited. Patients with max IMTs ≥1.1 mm showed significantly higher serum ICTP concentrations compared with patients with max IMTs <1.1 mm (3.33 ± 0.97 vs 2.82 ± 0.65 ng/mL, p<0.05). Serum ICTP concentration was also positively correlated with max IMT (p<0.001) or baPWV values (p<0.05). Multivariate analyses also revealed that serum ICTP concentrations were correlated with max IMT (p<0.001; 95% CI 0.200 to 0.454). These results suggest that serum ICTP concentrations can be used as a non-invasive biomarker for systemic atherosclerosis. (Tokushima University Institutional Repository) ● Metadata: 109666 (Link to Publication Site) ● Publication site (DOI): 10.1507/endocrj.EJ15-0589 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26877258 ● Summary page in Scopus @ Elsevier: 2-s2.0-84964267287 (Tokushima University Institutional Repository: 109666, DOI: 10.1507/endocrj.EJ15-0589, PubMed: 26877258, Elsevier: Scopus)
42.	Masato Miyake, Akitoshi Nomura, Atsushi Ogura, Kenji Takehana, Yoshihiro Kitahara, Kazuna Takahara, Kazue Tsugawa, Chinobu Miyamoto, Naoko Miura, Ryosuke Sato, Kiyoe Kurahashi, P Heather Harding, Miho Oyadomari, David Ron and Seiichi Oyadomari : Skeletal muscle-specific eukaryotic translation initiation factor 2 phosphorylation controls amino acid metabolism and fibroblast growth factor 21-mediated non-cell-autonomous energy metabolism., The FASEB journal, Vol.30, No.2, 798-812, 2015. (Summary) The eukaryotic translation initiation factor 2 (eIF2) phosphorylation-dependent integrated stress response (ISR), a component of the unfolded protein response, has long been known to regulate intermediary metabolism, but the details are poorly worked out. We report that profiling of mRNAs of transgenic mice harboring a ligand-activated skeletal muscle-specific derivative of the eIF2 protein kinase R-like ER kinase revealed the expected up-regulation of genes involved in amino acid biosynthesis and transport but also uncovered the induced expression and secretion of a myokine, fibroblast growth factor 21 (FGF21), that stimulates energy consumption and prevents obesity. The link between the ISR and FGF21 expression was further reinforced by the identification of a small-molecule ISR activator that promoted Fgf21 expression in cell-based screens and by implication of the ISR-inducible activating transcription factor 4 in the process. Our findings establish that eIF2 phosphorylation regulates not only cell-autonomous proteostasis and amino acid metabolism, but also affects non-cell-autonomous metabolic regulation by induced expression of a potent myokine.-Miyake, M., Nomura, A., Ogura, A., Takehana, K., Kitahara, Y., Takahara, K., Tsugawa, K., Miyamoto, C., Miura, N., Sato, R., Kurahashi, K., Harding, H. P., Oyadomari, M., Ron, D., Oyadomari, S. Skeletal muscle-specific eukaryotic translation initiation factor 2 phosphorylation controls amino acid metabolism and fibroblast growth factor 21-mediated non-cell-autonomous energy metabolism. (Tokushima University Institutional Repository) ● Metadata: 115105 (Link to Publication Site) ● Publication site (DOI): 10.1096/fj.15-275990 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26487695 ● Summary page in Scopus @ Elsevier: 2-s2.0-84958811791 (Tokushima University Institutional Repository: 115105, DOI: 10.1096/fj.15-275990, PubMed: 26487695, Elsevier: Scopus)

Review, Commentary:

1.	Ryosuke Sato, Masato Miyake, Kiyoe Kurahashi, Kazuna Takahara, 野村明利, 津川和江, Atsushi Ogura, Natsuo Yasui and Seiichi Oyadomari : 小胞体ストレス伝達蛋白質ATF4βは成長軟骨細胞の機能成熟に重要である, Pharma Medica, Vol.31, No.2, 163, Feb. 2013.
2.	Masato Miyake, Akitoshi Nomura, Kazuna Takahara, Atsushi Ogura, Ryosuke Sato, Kiyoe Kurahashi, Miho Oyadomari, Hiroshi Inoue and Seiichi Oyadomari : 骨格筋での小胞体ストレスなどからのeIF2αリン酸化によるエネルギー消費の制御と抗肥満作用, Pharma Medica, Vol.31, No.2, 161, Feb. 2013.

Proceeding of International Conference:

1.	Hiroki Yamagami, Tomoyo Hara, Yukari Mitsui, Shiho Masuda, Kiyoe Kurahashi, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Analysis of clinical factors involved in AGE accumulation in people with type 2 diabetes, IDF-WPR Congress 2023/15th Scientific Meeting of AASD, Jul. 2023.
2.	Yosuke Kaneko, Saya Yasui, Minae Hosoi, Akihiro Tani, Hiroki Yamagami, Hiroyasu Mori, Tomoyo Hara, Yukari Mitsui, Kiyoe Kurahashi, Sumiko Yoshida, Shingen Nakamura, Akio Kuroda, Toshiki Otoda, Tomoyuki Yuasa, Itsuro Endo, Takeshi Soeki, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Dehydroepiandrosterone sulfate and skeletal muscle disorders in patients with type 2 diabetes, IDF-WPR Congress 2023/15th Scientific Meeting of AASD, Tokyo, Jul. 2023.
3.	Yumi Kuwamura, Kiyoe Kurahashi, Sumiko Yoshida, Hiromichi Yumoto, Maki Hosoki, Yukihiro Momota, Ken-ichi Aihara, Masuko Sumikawa, Hirokazu Uemura, Munehide Matsuhisa and Itsuro Endo : Evaluation of Nursing Educational Material on Oral Health Behavior of Persons with Diabetes: Part 3 -- Physicians' Survey, International Diabetes Federation Western Pacific Congress 2023 /15th Scientific Meeting of Asian Association for the study of Diabetes, Kyoto, Japan, Jul. 2023.
4.	Tomoyo Hara, Hiroki Yamagami, Yukari Mitsui, Shiho Masuda, Kiyoe Kurahashi, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Clinical factors and glycemic control in Japanese people with type 2 diabetes treated with weekly Dulaglutide at a dose of 0.75 mg, IDF-WPR Congress 2023/15th Scientific Meeting of AASD, Jul. 2023.
5.	Minae Hosoki, Hiroki Yamagami, Taiki Hori, Saya Yasui, Tomoyo Hara, Kiyoe Kurahashi, Sumiko Yoshida, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa, Itsuro Endo, Masahiro Abe and Ken-ichi Aihara : Pharmaceutical Influences on In-hospital Death in Patients with and Those without Diabetes at a Japanese General Hospital, The 29th Scientific Meeting of the International Society of Hypertension, Oct. 2022.
6.	Shiho Masuda, Tomoyo Hara, Hiroki Yamagami, Mitsui Yukari, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Shingen Nakamura, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Evaluation of Vascular Function for Prediction of Renal Prognosis in Japanese Patients with Lifestyle-Related Diseases, The 29th Scientific Meeting of the International Society of Hypertension, Oct. 2022.
7.	Takeshi Harada, Asuka Oda, Yosuke Matsushita, Ryohei Sumitani, Yusuke Inoue, Tomoyo Hara, Masahiro Oura, Kimiko Sogabe, Tomoko Maruhashi, Mamiko Takahashi, Kiyoe Kurahashi, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Masahiro Hiasa, Jumpei Teramachi, Toyomasa Katagiri and Masahiro Abe : ADAR1-dsRNA metabolism in myeloma cells with 1q amplification: a novel therapeutic target, 19th International Myeloma Society Annual Meeting, Aug. 2022.
8.	Tomoyo Hara, Mitsui Yukari, Masuda Shiho, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Plasma heparin cofactor activity is inversely associated with the development NAFLD in patients with diabetes, American Diabetes Association 82nd Scientific Sessions, Jun. 2022.
9.	Hiroki Yamagami, Yasui Saya, Hosoki Minae, Hori Taiki, Tomoyo Hara, Kiyoe Kurahashi, Sumiko Yoshida, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa, Itsuro Endo, Masahiro Abe and Ken-ichi Aihara : Skin autofluorescence is associated with tubular injury represented by urinary excretion of liver-type fatty acid-binding protein in patients with diabetes, American Diabetes Association 82nd Scientific Sessions, Jun. 2022.
10.	Tomoyo Hara, Mitsui Yukari, Masuda Shiho, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Heparin cofactor II prevents the development of albuminuria in patients with diabetes, EASD 2021 57th Annual Meeting, Sep. 2021.
11.	Tomoyo Hara, H Yamagami, Y Mitsui, S Masuda, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Plasma heparin cofactor activity is inversely associated with the development NAFLD in patients with diabetes, American Diabetes Association 80th Scientific Session, Chicago, Jun. 2020.
12.	Yumi Kuwamura, Sumiko Yoshida, Kiyoe Kurahashi, Masuko Sumikawa, Eijiro Sakamoto, Akio Kuroda, Hikari Yamato, Misuzu Okamoto, Hirokazu Uemura, Daisuke Hinode, Hiromichi Yumoto, Ken-ichi Aihara, Makoto Funaki, Munehide Matsuhisa, Itsuro Endo and Sachi Kishida : Oral health behaviors of outpatients with diabetes based on the Revised Diabetes Oral Health Assessment Tool for nurses, Journal of Diabetes Investigation, Vol.10, No.Supplement1, 26, Sendai-City, Miyagi Prefecture, May 2019. (Keyword) oral health behaviors / diabetes nursing / assessment
13.	Yumi Kuwamura, Sumiko Yoshida, Kiyoe Kurahashi, Masuko Sumikawa, Eijiro Sakamoto, Ken-ichi Aihara, Hiromichi Yumoto, Munehide Matsuhisa, Itsuro Endo, Toshiyuki Yasui and Sachi Kishida : The Relationship Between the Modified Diabetes Oral Health Assessment Tool© for Nurses, Self-Efficacy Scale, and Outcome Expectancy Scale for Self-Care of Patients with Periodontal Disease, 2nd Technological Competency as Caring in the Health Sciences 2018, 63, Aug. 2018. (Keyword) nurse / diabetes mellitus / oral health / self-efficacy / outcome expectancy
14.	Keisuke Kitakaze, Kiyoe Kurahashi, Masato Miyake, Yoshimasa Hamada, Miho Oyadomari and Seiichi Oyadomari : Targeted Deletion of ATF4 in β-cells Leads to the Vulnerability and Dedifferentiation During ER Stress, American Diabetes Association 78th scientific sessions, Jun. 2018.
15.	Akio Kuroda, Misuzu Yamada, Yukari Tominaga, Reiko Suzuki, Motoyuki Tamaki, Yuko Akehi, Yuichi Takashi, Daisuke Otsuka, Eisuke Shimokita, Fuminori Tanihara, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Masahiro Abe, Kevin Ferreri and Munehide Matsuhisa : Detection of pancreatic beta cell DNA in the circulation using the amplification refractory mustation system PCR, American Diabetes Association 78th Scientific Sessions, Orlando, Jun. 2018.
16.	Munehide Matsuhisa, Hiroyasu Mori, Mami Ohishi, Masashi Ishizu, Reiko Suzuki, Ineko Takikawa, Satoshi Taniguchi, Motoyuki Tamaki, Yuko Akehi, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki and Akio Kuroda : The risk factors for rapid decline of renal function in Japanese patients with diabetes mellitus, American Diabetes Association 78th Scientific Sessions, Orlando, Jun. 2018.
17.	Sumiko Yoshida, Kiyoe Kurahashi, Akio Kuroda, Itsuro Endo, Ken-ichi Aihara, Seiji Fukumoto, Munehide Matsuhisa and Masahiro Abe : Changes of oxidative stress markers in patient of diabetes educational hospitalization., The Endocrine Society's Annual Meeting 2018, Chicago, Mar. 2018.
18.	Kana Morimoto, Masuda Shiho, Kiyoe Kurahashi, Motoyuki Tamaki, Takeshi Kondo, Sumiko Yoshida, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Akehi Yuko, Makoto Funaki, Seiji Fukumoto, Munehide Matsuhisa and Ken-ichi Aihara : Identification of clinical determinants for coefficient of variation of - intervals in patients with type 2 diabetes., International Conference on Diabetes and Its Complications 2017, Baltimore, Nov. 2017. (Keyword) therapy / 合併症
19.	Ken-ichi Aihara, Uemoto Ryoko, Ishikawa Kazue, Kana Morimoto, Kiyoe Kurahashi, Sumiko Yoshida, Tomoyuki Yuasa and Masahiro Abe : Heparin cofactor II, a serine protease inhibitor, is associated with albuminuria in humans and mice., International Conference on Diabetes and Its Complications 2017, Baltimore, Nov. 2017. (Keyword) heparin cofactor II / albuminuria
20.	Kiyoe Kurahashi, Itsuro Endo, Nakamura Maiko, Ohnishi Yukiyo, Takeshi Kondo, Aizawa Shinichi, Toshio Matsumoto, Seiji Fukumoto and Masahiro Abe : Glucose intolerance induced by persistent activation of calcium-sensing receptor, American Society for Bone and Mineral Research 2016 Annual Meeting, Atlanta, Sep. 2016.
21.	Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Kiyoe Kurahashi, Takeshi Kondo, Hirokazu Miki, Itsuro Endo, Toshio Matsumoto and Masahiro Abe : TAK-1 inhibition disrupts Pim-2-associated and Pim-2-independent key signaling pathways to effectively suppress tumor growth and restore bone formation in myeloma, American Society for Bone and Mineral Research 2016 Annual Meeting, Atlanta, Sep. 2016.
22.	Kana Morimoto, Kiyoe Kurahashi, Takeshi Kondo, Sumiko Yoshida, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : Analysis of sodium restriction-induced blood pressure reduction in hospitalized patients with type 2 diabetes mellitus, The 10th Congress of the Asian-Pacific Society of Atherosclerosis and Vascular Diseases, Tokyo, Jul. 2016.
23.	Takeshi Kondo, Itsuro Endo, Ken-ichi Aihara, nishi Oh Yukiyo, Bingzi Dong, Kiyoe Kurahashi, Sumiko Yoshida, Ryota Amachi, Masahiro Hiasa, Jumpei Teramachi, Masahiro Abe, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe : Serum carboxy-terminal telopeptide of type I collagen, as a marker for systemic atherosclerosis, ANZBMS 2015 Annual Meeting, Hobart, Sep. 2015.
24.	Kiyoe Kurahashi, 森智子, 宮本千伸, 津川和江, Miho Oyadomari, Kazuna Takahara, 木村千寿子, Masato Miyake, Toshio Matsumoto and Seiichi Oyadomari : Saturated Fatty Acids Predominantly Activate PERK Pathway via Altered Composition of the Endoplasmic Reticulum Membrane, and Reduce Insulin Secretion in Pancreatic Cell by Translation Attenuation, 75th ADA scientific sessions, Jun. 2015.
25.	Masato Miyake, Kiyoe Kurahashi and Seiichi Oyadomari : Identification and Characterization of a Small-molecule Inducer of ATF4 for Promoting Insulin Synthesis in Pancreatic cells, 74th ADA Scientific Sessions, Jun. 2014.
26.	Nomura Akitoshi, Masato Miyake, Atsushi Ogura, Kiyoe Kurahashi, Mori Tomoko, Tsugawa Kazue, Miyamoto Chinobu, Miho Oyadomari and Seiichi Oyadomari : Role of the PERK signaling pathway in metabolic process, International Symposium Hannover-Tokushima Research Communication, Aug. 2013.
27.	Masato Miyake, NOMURA AKITOSHI, Atsushi Ogura, Kazuna Takahara, Kiyoe Kurahashi, Ryosuke Sato, Miho Oyadomari, Hiroshi Inoue and Seiichi Oyadomari : Phosphorylation of eIF2 in skeletal muscle increases energy expenditure and are resistant to diet induced obesity., The American Diabetes Association's 73nd Scientific Sessions, Jul. 2013.

Proceeding of Domestic Conference:

1.	Tomoyo Hara, 横田海友, 清水一磨, 浅井孝仁, Hiroki Yamagami, 三井由加里, 桝田志保, Kiyoe Kurahashi, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara : 心血管疾患リスクを有する患者における可溶型DPP-4/CD26と動脈硬化指標との連関解析, 第56回日本動脈硬化学会総会, Jul. 2024.
2.	Tomoyo Hara, 横田海友, 清水一磨, 浅井孝仁, Hiroki Yamagami, 三井由加里, 桝田志保, Kiyoe Kurahashi, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara : 糖尿病患者における可溶型DPP-4/CD26と動脈硬化指標との関連, 第67日本糖尿病学会学術集会, May 2024.
3.	遠藤裕美, Tomoyo Hara, 清水一磨, 吉田麻衣子, 浅井孝仁, Hiroki Yamagami, Ryo Kanamura, Kiyoe Kurahashi and Itsuro Endo : 早期に治療介入できた免疫関連有害事象による1型糖尿病の1例, 第268回徳島医学会学術集会, Mar. 2024.
4.	浅井孝仁, Tomoyo Hara, 清水一磨, 吉田麻衣子, 山上絋規, 三井由加里, Kiyoe Kurahashi, Akio Kuroda, Munehide Matsuhisa and Itsuro Endo : ランレオチドを投与した14症例の糖代謝への影響に関する検討, 第33回臨床内分泌代謝Update, Nov. 2023.
5.	Tomoyo Hara, 清水一磨, 浅井孝仁, 吉田麻衣子, Hiroki Yamagami, 三井由加里, Kiyoe Kurahashi, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara : 2型糖尿病患者の非アルコール性脂肪性肝疾患における尿中可溶性ウロキナーゼ型プラスミノーゲン活性化受容体の臨床的意義, 第38回日本糖尿病合併症学会, Oct. 2023.
6.	清水一磨, Hiroki Yamagami, Tomoyo Hara, 答島悠貴, 浅井孝仁, 三井由加里, Kiyoe Kurahashi, Munehide Matsuhisa and Itsuro Endo : 診断に7年間を要したTSH産生下垂体micro adenomaの一例, 第33回臨床内分泌代謝Update, Oct. 2023.
7.	Yumi Kuwamura, 瀧川稲子, Hiromichi Yumoto, Maki Hosoki, Yukihiro Momota, 澄川真珠子, Kiyoe Kurahashi and Hirokazu Uemura : 糖尿病患者への口腔保健行動の看護支援教材の作成に向けてー第4報看護師を対象とした調査, 第28回日本糖尿病教育・看護学会学術集会, Vol.27, 149, Sep. 2023.
8.	Tomoyo Hara, Hiroki Yamagami, 三井由加里, Kiyoe Kurahashi, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa, Itsuro Endo and Ken-ichi Aihara : 2 型糖尿病患者における血圧・血糖管理目標達成下での腎糸球体・尿細管障害のリスク因子の検討, 第45回日本高血圧学会総会, Sep. 2023.
9.	Hiroki Yamagami, Tomoyo Hara, Yuki Tohjima, Takahito Asai, 三井由加里, Kiyoe Kurahashi, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : 2型糖尿病患者のSkin autofluorscenceを規定する因子の検討, 第96回日本内分泌学会学術総会, Jun. 2023.
10.	Hiroki Yamagami, Tomoyo Hara, Yuki Tohjima, Takahito Asai, 三井由加里, Kiyoe Kurahashi, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : 2型糖尿病患者のAGEs蓄積に関わる臨床的因子の解析, 第66回日本糖尿病学会年次学術集会, May 2023.
11.	Yuki Tohjima, Tomoyo Hara, Takahito Asai, Hiroki Yamagami, 三井由加里, Kiyoe Kurahashi, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara : 当院におけるインスリングラルギン/リキシセナチド (iGlarLixi)導入症例の臨床背景および効果の検討, 第66回日本糖尿病学会年次学術集会, May 2023.
12.	Yumi Kuwamura, Hiromichi Yumoto, Maki Hosoki, Yukihiro Momota, 澄川真珠子, Kiyoe Kurahashi and Sumiko Yoshida : 糖尿病がある人の口腔保健行動のチームでの支援にむけて第2報ブラッシングの継続支援の工夫に焦点をあてた報告, 第66回日本糖尿病学会年次学術集会, Vol.66, No.Supplement, S-316, May 2023.
13.	Tomoyo Hara, Yuki Tohjima, Takahito Asai, Hiroki Yamagami, 三井由加里, Kiyoe Kurahashi, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara : 糖尿病患者における腎糸球体および尿細管障害特異的なリスク因子の臨床的検討, 第66回日本糖尿病学会年次学術集会, May 2023.
14.	Yuki Tohjima, Tomoyo Hara, 浅井孝仁, Hiroki Yamagami, 三井由加里, Kiyoe Kurahashi, Sumiko Yoshida, Akio Kuroda, Munehide Matsuhisa, Seiji Fukumoto, Munehide Matsuhisa and Masahiro Abe : 首下がりを契機に診断に至ったCushing病の一例, 内科学会第127回四国地方会, Dec. 2022.
15.	Yuki Tohjima, 三井由加里, 浅井孝仁, Tomoyo Hara, Hiroki Yamagami, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Akio Kuroda, Masahiro Abe and Munehide Matsuhisa : レパグリニドとクロピドグレルの併用による遷延性低血糖を認めた一例, 日本糖尿病学会中国四国地方会第60回総会, Nov. 2022.
16.	Tomoyo Hara, Kiyoe Kurahashi, Hirofumi Hamano, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara : デュラグルチド使用中患者の HbA1c管理に影響を与える因子の検討, 日本糖尿病学会中国四国地方会第60回総会, Nov. 2022.
17.	Yumi Kuwamura, Hiromichi Yumoto, Maki Hosoki, Yukihiro Momota, 澄川真珠子, Sumiko Yoshida, Kiyoe Kurahashi and 瀧川稲子 : 糖尿病をもつ人の口腔保健行動のチームでの支援にむけて第1報歯科医師による口腔保健行動の支援と看護師への期待, 第27回日本糖尿病教育・看護学会学術集会, Vol.26, 145, Sep. 2022. (Keyword) diabetes mellitus / oral health behaviors / 看護師
18.	答島悠貴, Tomoyo Hara, 浅井孝仁, Hiroki Yamagami, 三井由加里, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo and Seiji Fukumoto : 低ALP血症を契機として，ALPL遺伝子解析を行い診断に至った成人型低ホスファターゼ血症の一例, 第22回日本内分泌学会四国支部学術集会, Sep. 2022.
19.	Tomoyo Hara, 浅井孝仁, 答島悠貴, Hiroki Yamagami, 三井由加里, Kiyoe Kurahashi, Sumiko Yoshida, Seiji Fukumoto and Itsuro Endo : 授乳中にPTHrP上昇による高Ca血症を呈した一例, 第22回日本内分泌学会四国支部学術集会, Sep. 2022.
20.	三井由加里, Akio Kuroda, Tomoyo Hara, Hiroki Yamagami, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Masahiro Abe and Munehide Matsuhisa : 持続皮下インスリン注入療法下 1 型糖尿病合併妊娠における分娩直後のインスリン投与設定変更の提案, 第22回日本糖尿病インフォマティクス学会年次学術集会, Aug. 2022.
21.	Shiho Masuda, Tomoyo Hara, 三井由加里, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara : 生活習慣病患者のeGFR年間変化量予測における血管内皮機能の意義, 第54回日本動脈硬化学会総会・学術集会, Jul. 2022.
22.	Tomoyo Hara, 山上紘規, 三井由加里, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara : 糖尿病患者における血漿Heparin Cofactor II活性とNAFLD病態指標の連関解析, 第8回肝臓と糖尿病・代謝研究会, Jun. 2022.
23.	Sumiko Yoshida, 辻誠一郎, Kiyoe Kurahashi, 宮恵子, 島久登, 田代学, 井上朋子, 水口潤, 中村信元, Akio Kuroda, Itsuro Endo, Masahiro Abe and Munehide Matsuhisa : 透析患者における新型コロナワクチン抗体と糖尿病の関連の検討, 第 65 回日本糖尿病学会年次学術集会, May 2022.
24.	Yumi Kuwamura, 澄川真珠子, Hiromichi Yumoto, Maki Hosoki, Yukihiro Momota, Sumiko Yoshida, Kiyoe Kurahashi and Hirokazu Uemura : コロナ禍で実施された糖尿病患者への教育・指導の方法についての文献による検討, 第65回日本糖尿病学会年次学術集会, Vol.65, No.Supplement, S233, May 2022.
25.	Sumiko Yoshida, 辻誠士郎, Kiyoe Kurahashi, 宮恵子, 島久登, 田代学, 井上朋子, 水口潤, Shingen Nakamura, Akio Kuroda, Itsuro Endo, Masahiro Abe and Munehide Matsuhisa : 透析患者における新型コロナワクチン抗体と糖尿病の関連の検討, Journal of the The Japan Diabetes Society, Vol.65, No.Suppl.1, S-165, Apr. 2022. (Keyword) 血液透析ウイルス抗体腎不全-慢性(治療) 糖尿病性腎症(治療) 予防接種 COVID-19ワクチン(治療的利用) *Tozinameran(治療的利用) ヒト男女
26.	Sumiko Yoshida, 辻誠士郎, 金子遥祐, 森建介, 河田沙紀, 川原綾香, 遠藤ふうり, Tomoyo Hara, Kiyoe Kurahashi, Akio Kuroda, 明比祐子, Itsuro Endo, Masahiro Abe and Munehide Matsuhisa : 精神疾患とうつ尺度が減量入院効果に及ぼす影響, 第41回日本肥満学会・第38回日本肥満症治療学会, Mar. 2022.
27.	辻誠士郎, Sumiko Yoshida, 金子遥祐, 森建介, 河田沙紀, 川原綾香, 遠藤ふうり, Tomoyo Hara, Kiyoe Kurahashi, Akio Kuroda, 明比祐子, Itsuro Endo, Masahiro Abe and Munehide Matsuhisa : 行動療法を重視した2週間の減量入院後の減量効果の検討, 第41回日本肥満学会・第38回日本肥満症治療学会, Mar. 2022.
28.	辻誠士郎, Sumiko Yoshida, 金子遥祐, 森建介, 河田沙紀, 川原綾香, 遠藤ふうり, Tomoyo Hara, Kiyoe Kurahashi, Akio Kuroda, 明比祐子, Itsuro Endo, Masahiro Abe and Munehide Matsuhisa : 行動療法を重視した2週間の減量入院後の減量効果の検討, 第42回日本肥満学会第39回日本肥満症治療学会学術集会, Mar. 2022.
29.	Sumiko Yoshida, 辻誠士郎, 金子遥祐, 森建介, 河田沙紀, 川原綾香, 遠藤ふうり, Tomoyo Hara, Kiyoe Kurahashi, 明比祐子, Itsuro Endo, Masahiro Abe and Munehide Matsuhisa : 精神疾患とうつ尺度が減量入院効果に及ぼす影響, 第42回日本肥満学会第39回日本肥満症治療学会学術集会, Mar. 2022.
30.	Tomoyo Hara, 河田沙紀, 川原綾香, 金子遥祐, 森建介, 三井由加里, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Seiji Fukumoto and Masahiro Abe : 低Mg血症によるPTH分泌不全により著明な低Ca血症を来した一例, 第33回日本老年医学会四国地方会, Jan. 2022. (Keyword) 副甲状腺
31.	森建介, Kiyoe Kurahashi, 河田沙紀, 川原綾香, 金子遥祐, 高丸利加子, Sumiko Yoshida, Itsuro Endo, Yasuhiko Nishioka and Masahiro Abe : 失語症のため治療説明に難渋し方針決定が遅れた異所性ACTH症候群の1例, 第33回日本老年医学会四国地方会, Jan. 2022.
32.	Sho Tanaka, Takumi Hari, Kazuki Fujiwara, Yuka Nomura, MATSUDA Wako, NAGAI Teruyuki, 大西幸代, Tomoyo Hara, Kiyoe Kurahashi, Ganbaatar Byambasuren, Mai Kanai and Itsuro Endo : ミトコンドリア移植による乳癌新規治療法開発の試み, 第45回徳島県医学検査学会, Dec. 2021.
33.	NAGAI Teruyuki, MATSUDA Wako, 大西幸代, Tomoyo Hara, Kiyoe Kurahashi, Ganbaatar Byambasuren, Mai Kanai and Itsuro Endo : 健常ミトコンドリア産生工場としての間葉系幹細胞, 第45回徳島県医学検査学会, Dec. 2021.
34.	青山理央, 川原綾香, Kiyoe Kurahashi, Tomoyo Hara, Sumiko Yoshida, Akio Kuroda, Munehide Matsuhisa, Munehide Matsuhisa, Seiji Fukumoto, Itsuro Endo and Masahiro Abe : 1型糖尿病とバセドウ病を同時に診断した1例, 日本内科学会第125回四国地方会, Dec. 2021.
35.	高岡俊, 金子遥祐, 辻誠士郎, Kiyoe Kurahashi, Sumiko Yoshida, 明比祐子, Itsuro Endo, Masahiro Abe and Seiji Fukumoto : レンバチニブで破壊性甲状腺炎をきたし，医原性副腎皮質機能低下症による副腎不全が顕在化した一例, 日本内科学会第125回四国地方会, Dec. 2021.
36.	Shiho Masuda, Tomoyo Hara, 三井由加里, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara : 生活習慣病患者におけるeGFR年間変化量と血管内皮機能の連関解析, 第6回日本糖尿病・生活習慣病ヒューマンデータ学会, Dec. 2021.
37.	Tomoyo Hara, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara : 糖尿病患者における血漿Heparin Cofactor II活性とNAFLD病態指標の連関, 第6回日本糖尿病・生活習慣病ヒューマンデータ学会, Dec. 2021. (Keyword) ヘパリンコファクターII / NAFLD / diabetes
38.	河田沙紀, Tomoyo Hara, Sumiko Yoshida, 川原綾香, Yohsuke Kaneko, Kensuke Mori, 遠藤ふうり, 辻誠士郎, 三井由加里, Kiyoe Kurahashi, 明比祐子, Itsuro Endo, Masahiro Abe and Seiji Fukumoto : アルドステロンを含む3種のホルモン産生副腎皮質癌の一例, 第32回臨床内分泌代謝Update, Nov. 2021.
39.	平岡栞名, Tomoyo Hara, 河田沙紀, 川原綾香, Yohsuke Kaneko, Kensuke Mori, 遠藤ふうり, 辻誠士郎, 三井由加里, Kiyoe Kurahashi, Sumiko Yoshida, 明比祐子, Yoshimi Bando, Itsuro Endo and Seiji Fukumoto : アドレナリン優位の上昇を示したパラガングリオーマの1例, 第31回臨床内分泌代謝Update, Nov. 2021.
40.	河田沙紀, Tomoyo Hara, Sumiko Yoshida, 川原綾香, 金子遥祐, 森建介, 遠藤ふうり, 辻誠士郎, 三井由加里, Kiyoe Kurahashi, 明比祐子, Itsuro Endo, Masahiro Abe and Seiji Fukumoto : アルドステロンを含む3種のホルモン産生性副腎皮質癌の一例, 第31回臨床内分泌代謝Update, Nov. 2021.
41.	森建介, 辻誠士郎, Sumiko Yoshida, 河田沙紀, 川原綾香, 金子遥祐, 細木美苗, 遠藤ふうり, Tomoyo Hara, 三井由加里, Kiyoe Kurahashi, Itsuro Endo, Seiji Fukumoto and Masahiro Abe : 10cmの右大腿部腫瘤を原因とする腫瘍性骨軟化症の1例, 第31回臨床内分泌Update, Nov. 2021.
42.	Sumiko Yoshida, 河田沙紀, 川原綾香, 金子遥祐, 森建介, 遠藤ふうり, 辻誠士郎, Tomoyo Hara, Kiyoe Kurahashi, 明比祐子, Itsuro Endo, Masahiro Abe and Seiji Fukumoto : 新型コロナワクチン投与後に発症した亜急性甲状腺炎の1例, 第64回日本甲状腺学会学術集会, Nov. 2021.
43.	川原綾香, Kiyoe Kurahashi, 河田沙紀, 金子遥祐, 遠藤ふうり, Tomoyo Hara, 辻誠士郎, Sumiko Yoshida, Akio Kuroda, Itsuro Endo and Munehide Matsuhisa : 肝膿瘍とサイトメガロウイルス胃炎を合併した2型糖尿病の一例, 日本糖尿病学会中国四国地方会第59回総会, Oct. 2021.
44.	金子遥祐, Tomoyo Hara, 河田沙紀, 川原綾香, 遠藤ふうり, 辻誠士郎, Kiyoe Kurahashi, Sumiko Yoshida, Akio Kuroda, Itsuro Endo and Munehide Matsuhisa : PD-1抗体が1型糖尿病発症に関与したと考えられる非典型的な3例(29文字), 日本糖尿病学会中国四国地方会第59回総会, Oct. 2021.
45.	河田沙紀, Kiyoe Kurahashi, 川原綾香, 金子遥祐, 遠藤ふうり, Tomoyo Hara, 辻誠士郎, Sumiko Yoshida, Akio Kuroda, Itsuro Endo and Munehide Matsuhisa : 糖尿病ケトアシドーシスが改善後にケトーシスが再燃した2型糖尿病の1例, 日本糖尿病学会中国四国地方会第59回総会, Oct. 2021.
46.	Asami Okada, Misuzu Yamada, Hiroyasu Mori, 明比祐子, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa and Akio Kuroda : 1型糖尿病患者における膵β細胞傷害の定量化の試み, 日本糖尿病学会中国四国地方会第59回総会, Oct. 2021.
47.	川原綾香, Tomoyo Hara, 平岡栞名, 辻誠士郎, 三井由加里, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Masahiro Abe and Seiji Fukumoto : 前立腺癌の副腎転移が123I-MIBGシンチグラフィ陽性を示した1例, 第21回日本内分泌学会四国支部学術集会, Sep. 2021.
48.	金子遥祐, Kiyoe Kurahashi, 水口槙子, Sumiko Yoshida, 明比祐子, Itsuro Endo and Seiji Fukumoto : 急速に右動眼神経麻痺が悪化したが，速やかに外科治療を行い寛解しえた13歳のクッシング病の一例, 第21回日本内分泌学会四国支部学術集会, Sep. 2021.
49.	Asami Okada, Misuzu Yamada, Hiroyasu Mori, 明比祐子, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa and Akio Kuroda : 循環血中遊離DNAを用いた膵β細胞障害の新規検出法の確立, 第263回徳島医学会学術集会, Aug. 2021.
50.	吉川紘平, 金子遥祐, 辻誠士郎, 河田沙紀, 川原綾香, 森健介, 遠藤ふうり, 原倫世, Kiyoe Kurahashi, Sumiko Yoshida, Akio Kuroda, 明比祐子, Itsuro Endo, Munehide Matsuhisa, Masahiro Abe and Seiji Fukumoto : TIA様発作を契機に診断されたインスリノーマの一例, 第263回徳島医学会, Aug. 2021.
51.	Yumi Kuwamura, 澄川真珠子, Maki Hosoki, Hiromichi Yumoto, Yukihiro Momota, Sumiko Yoshida, Kiyoe Kurahashi and Hirokazu Uemura : 糖尿病患者の口腔保健行動の看護支援のための教育教材の開発に向けてー第1報糖尿病患者の義歯に関する文献検討, Journal of the The Japan Diabetes Society, Vol.64, No.Supplement, May 2021. (Keyword) diabetes mellitus / oral health behaviors / nursing
52.	辻誠士郎, Sumiko Yoshida, 平岡栞名, Kohsuke Miyataka, Minae Hosoki, Tomoyo Hara, 三井由加里, Kiyoe Kurahashi, Akio Kuroda, 明比祐子, Itsuro Endo, Makoto Funaki, Seiji Fukumoto, Masahiro Abe and Munehide Matsuhisa : 行動療法を中心とした2週間の減量入院プログラムの退院後の減量効果, 第64回日本糖尿病学会年次学術集会, May 2021.
53.	Tomoyo Hara, 平岡栞名, Minae Hosoki, Kohsuke Miyataka, 辻誠士郎, 三井由加里, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Itsuro Endo and Ken-ichi Aihara : 糖尿病患者のアルブミン尿増加に関わる臨床因子の横断および縦断解析, 第9回日本高血圧学会臨床高血圧フォーラム, May 2021.
54.	遠藤理子, Kiyoe Kurahashi, 平岡栞名, 細木美苗, 宮高紘輔, 辻誠士郎, Sumiko Yoshida, Itsuro Endo, Munehide Matsuhisa and Masahiro Abe : 慢性膵炎の急性増悪を繰り返し，仮性脾動脈瘤の急速な増大を認めた一例, 第124回日本内科学会四国地方会(WEB開催), May 2021.
55.	Tomoyo Hara, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo and Munehide Matsuhisa : 血漿 Heparin Cofactor \|\| 活性とNAFLD病態指標の連関解析, 第94回日本内分泌学会学術総会, Apr. 2021.
56.	Tomoyo Hara, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara : 血漿Heparin Cofactor II活性とNAFLD病態指標の連関解析, 第94回日本内分泌学会学術総会, Apr. 2021.
57.	Mai Kanai, 長井輝幸, Itsuro Endo, 大西幸代, 原倫世, 三井由加里, Kiyoe Kurahashi, Sumiko Yoshida, 瀬部真由, Hiroshi Sakaue, Seiji Fukumoto, 松本俊夫 and 安倍正博 : TAK1阻害による炎症性サイトカイン誘導性骨格筋萎縮の改善, Folia endocrinologica Japonica, Vol.97, No.1, 365, Apr. 2021. (Keyword) cytokinesis / 筋萎縮症(遺伝学,病理学,実験的) / 骨格筋(病理学) / 腫瘍壊死因子アルファ / 核内受容体NR2C2(拮抗物質・阻害物質) / マウス / animal
58.	Ranko Kimura, Kiyoe Kurahashi, Minae Hosoki, 辻誠司郎, 三井由加里, Sumiko Yoshida, 明比祐子, Itsuro Endo, Seiji Fukumoto and Masahiro Abe : 繰り返す脆弱性骨折を契機に発見されたクッシング症候群の一例, 第262回徳島医学会学術集会, Mar. 2021.
59.	Minae Hosoki, Sumiko Yoshida, 平岡栞名, Kohsuke Miyataka, 辻誠士郎, Tomoyo Hara, 三井由加里, Kiyoe Kurahashi, Itsuro Endo and Masahiro Abe : 持続血糖モニタリングシステムを使用した遠隔診療が有効であった高齢1型糖尿病の2症例, 第32回日本老年医学会四国地方会, Feb. 2021.
60.	Teruyuki Nagai, Chihiro Yoshimoto, Wako Matsuda, Sonoka Aibara, 大西幸代, Tomoyo Hara, Kiyoe Kurahashi, Masahiro Abe, Mai Kanai and Itsuro Endo : TAK1阻害による炎症性サイトカイン誘導性筋萎縮の改善, 第44回徳島県医学検査学会, Dec. 2020.
61.	金山涼加, Kiyoe Kurahashi, 明比祐子, Koichi Okamoto, Shingen Nakamura, Sumiko Yoshida, Itsuro Endo, Tetsuji Takayama and Masahiro Abe : 潰瘍性大腸炎とバセドウ病の治療中に汎血球減少を契機に自己免疫性胃炎が判明した一例, 第123回日本内科学会四国地方会, Nov. 2020.
62.	Minae Hosoki, Furi Endo, 三井由加里, 平岡栞名, Kohsuke Miyataka, 辻誠士郎, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo and Masahiro Abe : 推奨量のヒドロコルチゾン補充で症状が改善しなかった中枢性副腎不全の一例, 第123回日本内科学会四国地方会, Nov. 2020.
63.	辻誠士郎, Sumiko Yoshida, Furi Endo, 平岡栞名, Minae Hosoki, Kohsuke Miyataka, 三井由加里, Kiyoe Kurahashi, 明比祐子, Itsuro Endo, Masahiro Abe and Seiji Fukumoto : 副腎皮質癌と舌癌を合併しがんゲノム検査を施行した一例, 第30回臨床内分泌代謝Update, Nov. 2020.
64.	Kohsuke Miyataka, Kiyoe Kurahashi, Sumiko Yoshida, 平岡栞名, Minae Hosoki, Furi Endo, 辻誠士郎, 三井由加里, 明比祐子, Itsuro Endo, Masahiro Abe and Seiji Fukumoto : glioblastomaを発症した神経線維腫症1型の1例, 第30回臨床内分泌代謝Update, Nov. 2020.
65.	Minae Hosoki, 三井由加里, 平岡栞名, Kohsuke Miyataka, 辻誠士郎, Tomoyo Hara, Shiho Masuda, Kiyoe Kurahashi, Sumiko Yoshida, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Masahiro Abe and Seiji Fukumoto : 顕性Cushing症候群を示し片側副腎切除を施行したBMAHの一例, 第30回臨床内分泌代謝update, Nov. 2020.
66.	平岡栞名, 三井由加里, 細木美苗, 宮高紘輔, 辻誠士朗, 三井由加里, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Akio Kuroda, Masahiro Abe and Munehide Matsuhisa : 原田病，重症筋無力症を合併した1型糖尿病の1例, 日本糖尿病学会中国四国地方会第58総会, Oct. 2020.
67.	辻誠士朗, Kiyoe Kurahashi, 平岡栞名, 細木美苗, 宮高紘輔, 三井由加里, Sumiko Yoshida, Akio Kuroda, Itsuro Endo, Masahiro Abe and Munehide Matsuhisa : びまん性膵腫大を契機に膵癌再発と診断したGAD抗体陽性の糖尿病の一例, 日本糖尿病学会中国四国地方会第58総会, Oct. 2020.
68.	Sumiko Yoshida, 工藤千晶, 辻本賀美, 安井沙耶, 遠藤ふうり, 桝田志保, 三井由加里, Kiyoe Kurahashi, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki, Seiji Fukumoto, Masahiro Abe and Munehide Matsuhisa : 血糖管理入院でのテストステロン値の変化の検討, 第63回日本糖尿病学会年次学術集会, Oct. 2020.
69.	Itsuro Endo, 近藤剛史, Kiyoe Kurahashi, Toshio Matsumoto, Masahiro Abe and Seiji Fukumoto : 家族歴を有するFGF23関連低リン血症性骨軟化症の一例, The Annual Meeting of the Japanese Society for Bone and Mineral Research Program & Abstracts, 150, Oct. 2020.
70.	Kiyoe Kurahashi, 村井純平, 堀太貴, Ryohei Sumitani, Takeshi Harada, Shingen Nakamura, Mai Kanai, Akiko Sakurai, 原倫世, 桝田志保, Sumiko Yoshida, Itsuro Endo, 松本俊夫, Masahiro Abe and Seiji Fukumoto : 高1,25(OH)2D血症による高Ca血症を来したホジキンリンパ腫の一例, The Annual Meeting of the Japanese Society for Bone and Mineral Research Program & Abstracts, 150, Oct. 2020. (Keyword) Calcitriol Dacarbazine(治療的利用) Doxorubicin(治療的利用) Hodgkin病(合併症,病理学,薬物療法) Vinblastine(治療的利用) *高カルシウム血症(病因,病理学,薬物療法) 免疫組織化学 Brentuximab Vedotin(治療的利用) ヒト高齢者(65~79) 男
71.	Kohsuke Miyataka, Kiyoe Kurahashi, Sumiko Yoshida, 平岡栞名, Minae Hosoki, Furi Endo, 辻誠士郎, 三井由加里, 明比祐子 and Itsuro Endo : 血中IgG4濃度が高値であった甲状腺眼症の一例, 第20回日本内分泌学会四国支部学術集会, Sep. 2020.
72.	Tomoyo Hara, Sumiko Yoshida, 平岡栞名, Minae Hosoki, Kohsuke Miyataka, Furi Endo, 辻誠士郎, 三井由加里, Kiyoe Kurahashi and Itsuro Endo : 当院での高張食塩水負荷試験実施例における新旧中枢性尿崩症診断基準の比較, 第20回日本内分泌学会四国支部学術集会, Sep. 2020.
73.	川原綾香, Kiyoe Kurahashi, 工藤千晶, 鎌田基夢, Shinsuke Katoh, Yukiko Tomioka, 辻本賀美, 安井沙耶, 遠藤ふうり, 桝田志保, 三井由加里, Sumiko Yoshida, Ken-ichi Aihara, Itsuro Endo, Seiji Fukumoto, Munehide Matsuhisa and Masahiro Abe : 歩行不能だったが，多職種の高度な連携と患者特性に配慮したケアにより自宅生活可能となった高度肥満症の一例, 第261回徳島医学会学術集会, Aug. 2020.
74.	平岡栞名, 三井由加里, Hirokazu Miki, Seidai Satou, Momoyo Azuma, 遠藤ふうり, 宮髙紘輔, 辻誠士郎, 桝田志保, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Seiji Fukumoto, Munehide Matsuhisa and Masahiro Abe : 発熱・全身リンパ節腫脹で発症し，リンパ節生検で診断しえた結核性リンパ節炎の一例, 第261回徳島医学会学術集会, Aug. 2020.
75.	Tomoyo Hara, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara : NAFLD病態指標血漿Heparin Cofactor IIの連関, 第52回日本動脈硬化学会総会・学術集会, Aug. 2020.
76.	三井由香里, 飯塚裕斗, 田中智明, Itsuro Endo, Kiyoe Kurahashi, Sumiko Yoshida, 山口佑樹, 山上紘規, 藤中雄一, 森本佳奈, 白神敦久, Seiji Fukumoto and Toshio Matsumoto : CRH負荷試験による副腎皮質機能低下症·不全症カットオフ値策定の試み, 第93回日本内分泌学会学術総会, Vol.96, No.1, 251, Jul. 2020.
77.	Sumiko Yoshida, 工藤千晶, 辻本賀美, 安井沙耶, 遠藤ふうり, 桝田志保, 三井由香里, Kiyoe Kurahashi, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa, Masahiro Abe and Seiji Fukumoto : 糖尿病教育入院でのテストステロン値の変化の検討, 第93回日本内分泌学会学術総会, Vol.96, No.1, 287, Jul. 2020.
78.	Tomoyo Hara, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Ken-ichi Aihara : NAFLD病態指標Fib4-indexと血漿Heparin Cofactor Ⅱの連関, 第52回日本動脈硬化学会総会・学術集会, Jul. 2020. (Keyword) NAFLD / Heparin Cofactor Ⅱ
79.	桝田志保, Sumiko Yoshida, 工藤千晶, 辻本賀美, 安井沙耶, 遠藤ふうり, 三井由加里, Kiyoe Kurahashi, Itsuro Endo and Masahiro Abe : 診断に時間を要したバセドウ病による甲状腺クリーゼの一例, 第31回日本老年医学会四国地方会, Feb. 2020.
80.	川原綾香, Kiyoe Kurahashi, 工藤千晶, 鎌田基夢, 加藤真介, 富岡有紀子, 辻本賀美, Saya Yasui, Furi Endo, Shiho Masuda, 三井由加里, Sumiko Yoshida, Ken-ichi Aihara, Itsuro Endo, Seiji Fukumoto, Munehide Matsuhisa and Masahiro Abe : 歩行不能だったが，多職種の密な連携と患者特性に配慮したケアにより自宅生活可能となった高度肥満症の一例, 第260回徳島医学会学術集会大塚講堂, Feb. 2020.
81.	水本健斗, 菊池結愛, Kiyoe Kurahashi, Akiko Sakurai, Mai Kanai, 大西幸代 and Itsuro Endo : カルシウム感知受容体活性型変異における耐糖能異常, 第43回徳島県医学検査学会, Dec. 2019.
82.	三井由加里, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, 白神敦久 and Munehide Matsuhisa : SGLT2阻害薬による正常血糖糖尿病ケトアシドーシスの1例, 日本糖尿病学会中国四国地方会第57回総会, Dec. 2019.
83.	Kiyoe Kurahashi, 工藤千晶, 鎌田基夢, Shinsuke Katoh, Yoshiko Suzuki, 秋月佐代, Yukiko Tomioka, Sumiko Yoshida, 明比祐子, Itsuro Endo and Munehide Matsuhisa : 療養環境整備に苦慮した，歩行不能の高度肥満症の一例, 日本糖尿病学会中国四国地方会第57回総会, Dec. 2019.
84.	Kiyoe Kurahashi, 工藤千晶, 鎌田基夢, Shinsuke Katoh, Yoshiko Suzuki, 秋月佐代, Yukiko Tomioka, Sumiko Yoshida, 明比祐子, Itsuro Endo and 松久宗英 : 療養環境整備に苦慮した，歩行不能の高度肥満症の一例, 日本糖尿病学会中国四国地方会第57回総会, Dec. 2019.
85.	三井由加里, Akio Kuroda, Masashi Ishizu, 桝田志保, Kiyoe Kurahashi, Sumiko Yoshida, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Masahiro Abe and Munehide Matsuhisa : 頻回インスリン注射療法下の1型糖尿病患者における基礎インスリン比率の検討, 日本糖尿病学会中国四国地方会第57回総会, Dec. 2019.
86.	桝田志保, Sumiko Yoshida, 安井沙耶, 辻本賀美, 工藤千晶, Furi Endo, 三井由加里, Kiyoe Kurahashi, Akio Kuroda, Itsuro Endo and Munehide Matsuhisa : 肥満外科手術後早期に基礎インスリン必要量が減少した高度肥満1型用尿病の1例, 日本糖尿病学会中国四国地方会第57回総会, Dec. 2019.
87.	Furi Endo, Sumiko Yoshida, 工藤千晶, 辻本賀美, 安井沙耶, 桝田志保, 三井由加里, Kiyoe Kurahashi, Akio Kuroda, Itsuro Endo and Munehide Matsuhisa : 免疫チェックポイント阻害薬関連1型糖尿病の5例, 日本糖尿病学会中国四国地方会第57回総会, Dec. 2019.
88.	安井沙耶, 桝田志保, 辻本賀美, 工藤千晶, Furi Endo, 三井由加里, Kiyoe Kurahashi, Sumiko Yoshida, Akio Kuroda, Itsuro Endo and Munehide Matsuhisa : 基礎インスリン適正化とスクエアボーラス導入で血糖管理が改善した1型糖尿病の1例, 日本糖尿病学会中国四国地方会第57回総会, Dec. 2019.
89.	三井由加里, Akio Kuroda, Masashi Ishizu, Kiyoe Kurahashi, Sumiko Yoshida, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Masahiro Abe and Munehide Matsuhisa : 頻回インスリン注射療法下の1型糖尿病患者における基礎インスリン比率の検討, 第19回日本先進糖尿病治療研究会・第17回1型糖尿病研究会, Nov. 2019.
90.	辻本賀美, 三井由加里, 工藤千晶, 安井沙耶, 遠藤ふうり, 桝田志保, Kiyoe Kurahashi, Sumiko Yoshida, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Masahiro Abe and Seiji Fukumoto : 勤務時間の影響で副腎皮質機能異常が疑われた2例, 日本内分泌学会第19回四国支部学術集会, Sep. 2019.
91.	工藤千晶, 枡田志保, 辻本賀美, 安井沙耶, 遠藤ふうり, 三井由加里, Kiyoe Kurahashi, Sumiko Yoshida, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Masahiro Abe, 新谷保実 and Seiji Fukumoto : 両側副腎偶発腫瘍で発見された123I-MIBGシンチ陰性の褐色細胞腫の一例, 日本内分泌学会第19回四国支部学術集会, Sep. 2019.
92.	安井沙耶, 桝田志保, Sumiko Yoshida, 辻本賀美, 工藤千晶, 遠藤ふうり, 三井由加里, Kiyoe Kurahashi, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki, Munehide Matsuhisa, Masahiro Abe and Seiji Fukumoto : 成長ホルモン分泌不全症と甲状腺機能低下症を呈した小児がん経験者の一例, 第259回徳島医学会学術集会(令和元年度夏期), Aug. 2019.
93.	Tomoyo Hara, 遠藤ふうり, 桝田志保, 三井由加里, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Itsuro Endo and Ken-ichi Aihara : 原発性アルドステロン症におけるエプレレノンの血管機能への影響, 第51回日本動脈硬化学会総会・学術集会, Jul. 2019.
94.	宮高絋輔, Sumiko Yoshida, Furi Endo, 枡田志保, 三井由加里, Kiyoe Kurahashi, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Seiji Fukumoto, Makoto Funaki, Yoshihiro Matsudate, Hiroshi Nokihara, Yasuhiko Nishioka, Masahiro Abe and Munehide Matsuhisa : 免疫チェックポイント阻害薬投与後に1型糖尿病を発症した2例, 第62回日本糖尿病学会年次学術集会, May 2019.
95.	Mai Kanai, 松岡飛翔, Itsuro Endo, 大西幸代, Yuichi Takashi, Kiyoe Kurahashi, Sumiko Yoshida, Ken-ichi Aihara, Masahiro Abe, Seiji Fukumoto and Toshio Matsumoto : 鉄製剤投与によるFGF23関連低リン血症モデル作成の試み, 第92回日本内分泌学会学術総会, Vol.95, No.1, 422, May 2019.
96.	Kohsuke Miyataka, Furi Endo, 三井由加里, 枡田志保, Kiyoe Kurahashi, Sumiko Yoshida, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki, Seiji Fukumoto, Hiroshi Nokihara, Yasuhiko Nishioka, Masahiro Abe and Munehide Matsuhisa : 抗PD-1抗体投与後に1型糖尿病を発症した1例, 第258回徳島医学会学術集会ポスターセッション, Feb. 2019.
97.	Tetsuya Hida, 中島美世, Yoshihiro Matsudate, Kiyoe Kurahashi, Takanori Shikiji and 市原新一郎 : 下腹部に生じたelephantiasis nostras verrucosaの1例, 150回日本皮膚科学会徳島地方会, Nov. 2018.
98.	山川哲生, Masato Miyake, Masatoshi Morimoto, Satoshi Hisanaga, Kiyoe Kurahashi, 宮本千伸, 津川和江, Miho Oyadomari and Seiichi Oyadomari : ERK経路下流因子ncRNAによる癌増殖機構の解析, 第13回小胞体ストレス研究会, Nov. 2018.
99.	Sumiko Yoshida, 原倫世, 山口佑樹, Takeshi Kondo, 遠藤ふうり, 筒井康継, 桝田志保, Kiyoe Kurahashi, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Masahiro Abe, Kohhei Nakajima and Seiji Fukumoto : 急速に腫瘍が増大し悪性転化が疑われたCushing病の1例, 第28回臨床内分泌代謝Update, Nov. 2018.
100.	Tomoyo Hara, Sumiko Yoshida, 細井美希, 遠藤ふうり, 筒井康継, 桝田志保, Kiyoe Kurahashi, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Kohhei Nakajima, Yoshimi Bando, Masahiro Abe and Seiji Fukumoto : 脳内，副鼻腔，下垂体に炎症を認めステロイドが著効した1例, 第22回日本臨床内分泌病理学会学術総会, Oct. 2018.
101.	Kiyoe Kurahashi, Itsuro Endo, Takeshi Kondo, 遠藤ふうり, 原倫世, 桝田志保, Sumiko Yoshida, 明比祐子, Yoshimi Bando, Ken-ichi Aihara, Masahiro Abe and Seiji Fukumoto : ソマトスタチンアナログ製剤にて著明な縮小がみられたGH産生マクロアデノーマの1例, 第22回日本臨床内分泌病理学会, Sep. 2018.
102.	Kiyoe Kurahashi, Furi Endo, 桝田志保, Sumiko Yoshida, Akio Kuroda, Ken-ichi Aihara, Seiji Fukumoto, Itsuro Endo and Munehide Matsuhisa : 足趾上腕血圧比定値を契機に末梢動脈疾患を診断しえた，重症下肢軟部組織感染症を繰り返す2型糖尿病の一例, 第3回日本下肢救済・足病学会中国四国地方会学術集会, Sep. 2018.
103.	桝田志保, Itsuro Endo, 遠藤ふうり, 原倫世, 筒井康継, Kiyoe Kurahashi, Sumiko Yoshida, Tomoteru Kishimoto, Ken-ichi Aihara and Seiji Fukumoto : hCG,FSH製剤の併用によりパートナーの妊娠が確認された低ゴナドトロピン性男性性腺機能低下症の2例, 第18回日本内分泌学会四国支部学術集会, Sep. 2018.
104.	中村昌史, Tomoyo Hara, Kiyoe Kurahashi, 遠藤ふうり, 筒井康継, 桝田志保, Sumiko Yoshida, 明比祐子, Itsuro Endo and Seiji Fukumoto : 股関節痛と歩行困難を契機に診断したCushing症候群の一例, 第18回日本内分泌学会四国支部学術集会, Sep. 2018.
105.	Ken-ichi Aihara, Sumiko Yoshida, Furi Endo, 筒井康継, Tomoyo Hara, 桝田志保, Kiyoe Kurahashi, Toshiki Otoda, Tomoyuki Yuasa, Itsuro Endo, Kana Morimoto, Akio Kuroda, 明比祐子, Makoto Funaki, Munehide Matsuhisa, Seiji Fukumoto and Masahiro Abe : 原発性アルドステロン症におけるミネラルコルチコイド受容体拮抗薬の血管機能への影響, 第18回日本内分泌学会四国支部学術集会, Sep. 2018.
106.	Hiroyasu Mori, Michiko Araki, Akio Kuroda, Masashi Ishizu, Yuichi Takashi, Satoshi Taniguchi, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Motoyuki Tamaki, 明比祐子 and Munehide Matsuhisa : 1型糖尿病患者の血清IGF-1とサルコペニア合併に関する横断的検証, 第18回日本内分泌学会四国支部学術集会, Sep. 2018.
107.	山上紘規, Sumiko Yoshida, 遠藤ふうり, 原倫世, 筒井康継, 桝田志保, Kiyoe Kurahashi, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Yusuke Osaki, Ryuji Kaji, Yuichi Takashi, Masahiro Abe and Seiji Fukumoto : 壊死性ミオパチーを合併したX連鎖性低リン血症性くる病・骨軟化症の一例, 第18回日本内分泌学会四国支部学術集会, Sep. 2018.
108.	Itsuro Endo, 大西幸代, Kiyoe Kurahashi, Jumpei Teramachi, Masahiro Hiasa, Hirofumi Tenshin, Seiji Fukumoto, Masahiro Abe and Toshio Matsumoto : カルシウム感知受容体活性型変異マウスにおける骨強度の低下, 第36回日本骨粗鬆症学会各術集会, Jul. 2018.
109.	Sumiko Yoshida, 原倫世, 桝田志保, Kiyoe Kurahashi, Akio Kuroda, Itsuro Endo, Ken-ichi Aihara, Masahiro Abe and Munehide Matsuhisa : 高齢者における糖尿病教育入院中の体組成の変化, 第60回日本老年医学会学術集会, Jun. 2018.
110.	Akio Kuroda, Misuzu Yamada, 冨永ゆかり, 鈴木麗子, Motoyuki Tamaki, 明比祐子, Yuichi Takashi, Masashi Ishizu, 古賀大輔, Issei Imoto, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Masahiro Abe, Kevin Ferreri and Munehide Matsuhisa : 膵β細胞特異的PCRによる膵β細胞死の検出, 第61回日本糖尿病学会年次学術集会, May 2018.
111.	Sumiko Yoshida, 原倫世, 細井美希, 山上紘規, 山口佑樹, 桝田志保, Kiyoe Kurahashi, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki, Seiji Fukumoto, Masahiro Abe and Munehide Matsuhisa : 糖尿病教育入院における筋肉量の変化, 第61回日本糖尿病学会年次学術集会, May 2018.
112.	山上紘規, Sumiko Yoshida, 原倫世, 細井美希, 山口佑樹, 桝田志保, Kiyoe Kurahashi, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki, Seiji Fukumoto, Masahiro Abe, Yoshihiro Matsudate and Munehide Matsuhisa : 免疫チェックポイント阻害薬投与後に甲状腺機能異常と劇症1型糖尿病を発症した1例, 第61回日本糖尿病学会年次学術集会, May 2018.
113.	Ken-ichi Aihara, 上元良子, 石川カズ江, Kana Morimoto, 桝田志保, Hiroki Yamagami, Yuki Yamaguchi, Tomoyo Hara, 細井美希, Kiyoe Kurahashi, Sumiko Yoshida, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, 明比祐子, Itsuro Endo, Makoto Funaki, Seiji Fukumoto, Munehide Matsuhisa, Hiroyuki Azuma and Masahiro Abe : 生活習慣病患者の尿中酸化ストレス指標における糖尿病および薬物療法の影響, 第61回日本糖尿病学会年次学術集会, May 2018.
114.	Sumiko Yoshida, 原倫世, 細井美希, 山上紘規, 山口佑樹, 桝田志保, Kiyoe Kurahashi, Akio Kuroda, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki, Seiji Fukumoto, Daisuke Hamada, Munehide Matsuhisa and Masahiro Abe : 待機的高リスク整形外科手術における血糖管理の効果, 第91回日本内分泌学会学術総会, Apr. 2018.
115.	Tomoyo Hara, 桝田志保, Sumiko Yoshida, 細井美希, 山上紘規, 山口佑樹, Kiyoe Kurahashi, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Masahiro Abe : 急性合併症を来した高齢1型糖尿病の2症例, 第29回日本老年医学会四国地方会, Feb. 2018.
116.	Tomoyo Hara, Kiyoe Kurahashi, Kana Morimoto, 細井美希, Hiroki Yamagami, 山口佑樹, 桝田志保, Sumiko Yoshida, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa, Yoshimi Bando and Seiji Fukumoto : オクトレオチドが有効であったGH-TSH同時産生下垂体腺腫の一例, 第27回臨床内分泌代謝Update, Nov. 2017.
117.	桝田志保, 明比祐子, Sumiko Yoshida, Hiroki Yamagami, Yuki Yamaguchi, 細井美希, Tomoyo Hara, Kiyoe Kurahashi, Itsuro Endo, Akio Kuroda, Ken-ichi Aihara, Munehide Matsuhisa, Makoto Funaki and 福本誠ニ : 123I-MIBGシンチグラフィ陽性の副腎皮質腺腫の一例, 第27回臨床内分泌代謝Update抄録集, Nov. 2017.
118.	細井美希, Kana Morimoto, Takeshi Kondo, Hiroki Yamagami, Yuki Yamaguchi, Tomoyo Hara, 桝田志保, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, 明比祐子, Akio Kuroda, Ken-ichi Aihara, Munehide Matsuhisa and 福本誠ニ : 多発性骨髄腫治療を契機にプランマー病と判明した一例, 第27回臨床内分泌代謝Update抄録集, Nov. 2017.
119.	Yuki Yamaguchi, Sumiko Yoshida, Tomoyo Hara, 細井美希, Hiroki Yamagami, 桝田志保, Kiyoe Kurahashi, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki, 福本誠ニ, Masahiro Abe, Hideya Kashihara, Kouzou Yoshikawa and Munehide Matsuhisa : 高度肥満症に対するスリーブ状胃切除術の長期の耐糖能異常改善効果の検討, 日本糖尿病学会中国四国地方会第55回総会抄録集, Nov. 2017.
120.	Naoto Kunikata, Sumiko Yoshida, Tomoyo Hara, 細井美希, Hiroki Yamagami, Yuki Yamaguchi, 桝田志保, Kiyoe Kurahashi, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki, 福本誠ニ, Masahiro Abe, Daisuke Hamada and Munehide Matsuhisa : 待機的整形外科手術の術後経過における糖尿病の影響, 日本糖尿病学会中国四国地方会第55回総会抄録集, Nov. 2017.
121.	細井美希, Kiyoe Kurahashi, Tomoyo Hara, Yuki Yamaguchi, Hiroki Yamagami, 桝田志保, Sumiko Yoshida, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki, 福本誠ニ and Munehide Matsuhisa : 低血糖脳症をきたしたACTH単独欠損症合併1型糖尿病の一例, 日本糖尿病学会中国四国地方会第55回総会抄録集, Nov. 2017.
122.	山上紘規, Kiyoe Kurahashi, 原倫世, 細井美希, 山口佑樹, 桝田志保, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara and Seiji Fukumoto : 副腎クリーゼと急性膵炎を発症した21‐水酸化酵素欠損症の1例, 第117回日本内科学会四国地方会, Nov. 2017.
123.	Hiroyasu Mori, Mami Ohishi, 鈴木麗子, Akio Kuroda, Satoshi Taniguchi, Motoyuki Tamaki, 明比祐子, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki and Munehide Matsuhisa : 2型糖尿病患者における末梢神経障害の合併が骨格筋力の質的低下に及ぼす影響, 第32回日本糖尿病合併症学会, Oct. 2017.
124.	原倫世, Sumiko Yoshida, 山上紘規, 山口佑樹, 細井美希, 桝田志保, Kiyoe Kurahashi, Itsuro Endo, 明比祐子, Akio Kuroda, Ken-ichi Aihara, Munehide Matsuhisa, Makoto Funaki and Seiji Fukumoto : Frequent syncope and marked blood pressure fluctuation due to antiparkinson drugs: A case report, 2017年10月20日-22日ひめぎんホール, Oct. 2017.
125.	Tomoyo Hara, Sumiko Yoshida, 山上紘規, 山口佑樹, 細井美希, 桝田志保, Kiyoe Kurahashi, Itsuro Endo, 明比祐子, Akio Kuroda, Ken-ichi Aihara, Munehide Matsuhisa, Makoto Funaki and Seiji Fukumoto : 抗パーキンソン病薬により頻回な失神と著明な血圧変動をきたした一例, 第40回日本高血圧学会総会, Oct. 2017.
126.	張君, Masato Miyake, Kiyoe Kurahashi, 宮本千伸, 津川和江, Miho Oyadomari and Seiichi Oyadomari : 高血糖に伴うIRE1のO-GlcNAc修飾は小胞体ストレス応答を減弱させる, 第12回小胞体ストレス研究会, Oct. 2017.
127.	山川哲生, Masatoshi Morimoto, 久永哲, Masato Miyake, Kiyoe Kurahashi, 宮本千伸, 津川和江, Miho Oyadomari and Seiichi Oyadomari : 新規PERK経路下流因子Snhg12ホモ欠損マウス解析, 第12回小胞体ストレス研究会, Oct. 2017.
128.	山上紘規, Kiyoe Kurahashi, 山口佑樹, 細井美希, 原倫世, 桝田志保, Sumiko Yoshida, Itsuro Endo, 明比祐子, Akio Kuroda, Ken-ichi Aihara, Munehide Matsuhisa, Makoto Funaki and Seiji Fukumoto : バセドウ病とTSH産生下垂体腺腫の合併の一例, 第60回日本甲状腺学会学術集会, Oct. 2017.
129.	細井美希, Sumiko Yoshida, 山上紘規, 山口佑樹, 原倫世, 桝田志保, Kiyoe Kurahashi, Itsuro Endo, 明比祐子, Akio Kuroda, Ken-ichi Aihara, Munehide Matsuhisa, Makoto Funaki and Seiji Fukumoto : 無セルロプラスミン血症に合併した甲状腺乳頭癌の一例, 第60回日本甲状腺学会学術集会, Oct. 2017.
130.	桝田志保, Kiyoe Kurahashi, Takeshi Kondo, 細井美希, Yuki Yamaguchi, Tomoyo Hara, Hiroki Yamagami, Sumiko Yoshida, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa, Makoto Funaki and 福本誠ニ : デノスマブ投与により術後の血清Ca/P値を容易に管理しえた巨大異所性副甲状腺腺腫の一例, 第17回日本内分泌学会四国支部学術集会抄録集, Sep. 2017.
131.	Tomoyo Hara, Sumiko Yoshida, Yuki Yamaguchi, 細井美希, Hiroki Yamagami, 桝田志保, Kiyoe Kurahashi, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa, Makoto Funaki, 福本誠ニ and Masahiro Abe : 当院での免疫チェックポイント阻害薬による下垂体機能低下症の5例, 第17回日本内分泌学会四国支部学術集会抄録集, Sep. 2017.
132.	山口佑樹, Sumiko Yoshida, 細井美希, 山上紘規, 原倫世, 桝田志保, Kiyoe Kurahashi, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa, Makoto Funaki, Seiji Fukumoto and Hiromitsu Takizawa : 当院での免疫チェックポインント阻害薬による内分泌異常の発生と有害事象対策, 第255回徳島医学会学術集会(平成29年度夏期), Aug. 2017.
133.	Sumiko Yoshida, Ken-ichi Aihara, Kiyoe Kurahashi, Itsuro Endo and Masahiro Abe : 骨格筋のアンドロゲン受容体と耐糖能異常, 第35回内分泌代謝学サマーセミナー, Jul. 2017.
134.	Kana Morimoto, 桝田志保, Kiyoe Kurahashi, Motoyuki Tamaki, Takeshi Kondo, Sumiko Yoshida, Tomoyuki Yuasa, Akio Kuroda, Itsuro Endo, Seiji Fukumoto, Munehide Matsuhisa, Masahiro Abe, Hiroyuki Azuma and Ken-ichi Aihara : 生活習慣病患者における血管内皮機能制御に関わる臨床指標の検討, 第49回日本動脈硬化学会総会・学術集会, Jul. 2017.
135.	西山美月, Kiyoe Kurahashi, 桝田志保, Takeshi Kondo, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, 小松まち子, Seiji Fukumoto and Masahiro Abe : 維持透析中に管理困難な高Ca血症を契機に診断されたサルコイドーシスの一例, 第116回日本内科学会四国地方会, May 2017.
136.	Sumiko Yoshida, Ken-ichi Aihara, Kiyoe Kurahashi, Takeshi Kondo, Kana Morimoto, Motoyuki Tamaki, Tomoyuki Yuasa, Akio Kuroda, 明比祐子, Itsuro Endo, Makoto Funaki, 福本誠ニ and Munehide Matsuhisa : 糖尿病教育入院での酸化ストレスマーカーの変化の検討, 第60回日本糖尿病学会年次学術集会抄録集, May 2017.
137.	Motoyuki Tamaki, Akio Kuroda, Kiyoe Kurahashi, Ken-ichi Aihara, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, 山口普史, 白神敦久 and Munehide Matsuhisa : 課程用電気筋刺激装置(EMS)の10週間継続使用は運動障害を有する2型糖尿病患者の血糖コントロールを改善する, 第60回日本糖尿病学会年次学術集会抄録集, May 2017.
138.	Kana Morimoto, 桝田志保, Kiyoe Kurahashi, Motoyuki Tamaki, Takeshi Kondo, Sumiko Yoshida, Tomoyuki Yuasa, Akio Kuroda, 明比祐子, Itsuro Endo, Makoto Funaki, 福本誠ニ, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : 糖尿病患者における自律神経機能をアルブミン尿の相互関連および各病態に影響を及ぼす因子解析, 第60回日本糖尿病学会年次学術集会, May 2017.
139.	Michiko Araki, Hiroyasu Mori, Akio Kuroda, 鈴木麗子, Mami Ohishi, Satoshi Taniguchi, Motoyuki Tamaki, 明比祐子, Hiroshi Sakaue, Kiyoe Kurahashi, Takeshi Kondo, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki and Munehide Matsuhisa : 1型糖尿病患者における血清IGF-1とサルコペニア罹患との関連, 第60回日本糖尿病学会年次学術集会, May 2017.
140.	Hiroyasu Mori, Akio Kuroda, Michiko Araki, 鈴木麗子, Mami Ohishi, Satoshi Taniguchi, Motoyuki Tamaki, 明比祐子, Kiyoe Kurahashi, Takeshi Kondo, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki and Munehide Matsuhisa : 2型糖尿病患者における皮下AGE蓄積が筋機能低下に及ぼす影響, 第60回日本糖尿病学会年次学術集会抄録集, May 2017.
141.	張君, Masato Miyake, Kiyoe Kurahashi, 宮本千伸, 津川和江, 尾野雅哉, Miho Oyadomari and Seiichi Oyadomari : 高血糖に伴うIRE1のO-GlcNAc修飾は小胞体ストレス応答を減弱させる, 第60回日本糖尿病学会年次学術集会, May 2017.
142.	Sumiko Yoshida, Akio Kuroda, Minoru Irahara, Kiyoe Kurahashi, Takeshi Kondo, Itsuro Endo, Ken-ichi Aihara and Munehide Matsuhisa : 加重型妊娠高血圧腎症を来し集学的治療で分娩に至った糖尿病腎症の2症例, 第6回臨床高血圧フォーラム, May 2017.
143.	Sumiko Yoshida, Ken-ichi Aihara, Kiyoe Kurahashi, Takeshi Kondo, Itsuro Endo, Tomoyuki Yuasa, Seiji Fukumoto and Masahiro Abe : 骨格筋におけるアンドロゲン受容体の耐糖能への影響, 第90回日本内分泌学会学術総会, Apr. 2017.
144.	Kana Morimoto, Yuka Takahashi, Saori Yamashita, 上元良子, 石川カズ江, Kiyoe Kurahashi, Takeshi Kondo, Sumiko Yoshida, Akio Kuroda, Itsuro Endo, Tomoyuki Yuasa, Munehide Matsuhisa, 東博之, Masahiro Abe and Ken-ichi Aihara : 生活習慣病患者の血管内皮機能に関わる因子の臨床的検討, 第90回日本内分泌学会学術集会抄録集, Apr. 2017.
145.	Hiroyasu Mori, Akio Kuroda, Michiko Araki, 鈴木麗子, Mami Ohishi, Satoshi Taniguchi, Motoyuki Tamaki, 明比祐子, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki and Munehide Matsuhisa : 2型糖尿病患者におけるサルコペニアのリスク因子解析, 第51回日本成人病学会学術集会, Jan. 2017.
146.	桝田志保, Sumiko Yoshida, Kiyoe Kurahashi, Takeshi Kondo, Itsuro Endo, Masahiro Abe, Akio Kuroda, Munehide Matsuhisa, Ken-ichi Aihara and Seiji Fukumoto : メーグルコシダーゼ阻害薬による腸管気腫症の一例, 第115回日本内科学会四国地方会, Nov. 2016.
147.	Tomoyo Hara, Kiyoe Kurahashi, Takeshi Kondo, Sumiko Yoshida, Itsuro Endo, Akio Kuroda, Munehide Matsuhisa, Ken-ichi Aihara and Seiji Fukumoto : イピリムマブ投与後に続発性副腎不全を発症した一例, 第115回日本内科学会四国地方会, Nov. 2016.
148.	上田浩之, Itsuro Endo, Takeshi Kondo, Kiyoe Kurahashi, Sumiko Yoshida, Masahiro Abe, Akio Kuroda, Munehide Matsuhisa, Ken-ichi Aihara and Seiji Fukumoto : デノスマブによる耐糖能改善, 第115回日本内科学会四国地方会, Nov. 2016.
149.	Takeshi Kondo, Itsuro Endo, 明比祐子, Kiyoe Kurahashi, Motoyuki Tamaki, Sumiko Yoshida, Akio Kuroda, Ken-ichi Aihara, Munehide Matsuhisa, Masahiro Abe and Seiji Fukumoto : 免疫チェックポイント阻害剤で中枢性副腎不全を来した2例, 第26回臨床内分泌代謝Update, Nov. 2016.
150.	岡本恵暢, Sumiko Yoshida, Kiyoe Kurahashi, Takeshi Kondo, Kana Morimoto, Motoyuki Tamaki, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki, Munehide Matsuhisa and Seiji Fukumoto : IGF-2産生神経内分泌癌による重症低血糖の一例, 第26回臨床内分泌代謝Update, Nov. 2016.
151.	Sumiko Yoshida, Kiyoe Kurahashi, Takeshi Kondo, Kana Morimoto, Motoyuki Tamaki, Akio Kuroda, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki, Munehide Matsuhisa and Seiji Fukumoto : 当院のニボルマブおよびイピリムマブ投与21例の内分泌異常の検討, 第26回臨床内分泌代謝Update, Nov. 2016.
152.	山下沙織, Sumiko Yoshida, 高橋優花, Ken-ichi Aihara, Kiyoe Kurahashi, Takeshi Kondo, Kana Morimoto, Motoyuki Tamaki, Tomoyuki Yuasa, Akio Kuroda, 明比祐子, Itsuro Endo, Makoto Funaki, Seiji Fukumoto, Munehide Matsuhisa and Masahiro Abe : 糖尿病教育入院における酸化ストレス減少に影響を及ぼす因子の検討, 日本糖尿病学会中国四国地方会第54回総会, Nov. 2016.
153.	Michiko Araki, Hiroyasu Mori, Akio Kuroda, 鈴木麗子, Mami Ohishi, Satoshi Taniguchi, Motoyuki Tamaki, 明比祐子, Hiroshi Sakaue, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki and Munehide Matsuhisa : 1型糖尿病患者の血清IGF-1がサルコペニア罹患に及ぼす影響, 日本糖尿病学会中国四国地方会第54回総会, Nov. 2016.
154.	Hiroyasu Mori, Akio Kuroda, Michiko Araki, 鈴木麗子, Mami Ohishi, Satoshi Taniguchi, Motoyuki Tamaki, 明比祐子, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki and Munehide Matsuhisa : 2型糖尿病患者におけるAGE蓄積とサルコペニアとの関連の検討, 日本糖尿病学会中国四国地方会第54回総会, Nov. 2016.
155.	荒瀬美晴, Takeshi Kondo, Akio Kuroda, Kiyoe Kurahashi, Motoyuki Tamaki, Sumiko Yoshida, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Seiji Fukumoto, Masahiro Abe and Munehide Matsuhisa : 術前後で持続血糖モニター(CGM)を比較したアドレナリン優位褐色細胞腫の二例, 日本糖尿病学会中国四国地方会第54回総会, Nov. 2016.
156.	上田浩之, Takeshi Kondo, Akio Kuroda, Kiyoe Kurahashi, Motoyuki Tamaki, Sumiko Yoshida, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Seiji Fukumoto, Masahiro Abe and Munehide Matsuhisa : 基礎インスリンが不要であった膵性糖尿病の一例, 日本糖尿病学会中国四国地方会第54回総会, Nov. 2016.
157.	Kana Morimoto, 桝田志保, Kiyoe Kurahashi, Motoyuki Tamaki, Takeshi Kondo, Sumiko Yoshida, Tomoyuki Yuasa, Akio Kuroda, 明比祐子, Itsuro Endo, Makoto Funaki, Seiji Fukumoto, Munehide Matsuhisa, Masahiro Abe and Ken-ichi Aihara : 糖尿病患者における心電図R-R間隔変動係数に影響を及ぼす因子の検討, 日本糖尿病学会中国四国地方会第54回総会, Nov. 2016.
158.	Michiko Araki, Hiroyasu Mori, Akio Kuroda, 鈴木麗子, Mami Ohishi, Satoshi Taniguchi, Motoyuki Tamaki, 明比祐子, Hiroshi Sakaue, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki and Munehide Matsuhisa : 1型糖尿病患者の血清IGF-1がサルコペニア罹患に及ぼす影響, 第14回1型糖尿病研究会, Nov. 2016.
159.	Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Kiyoe Kurahashi, Takeshi Kondo, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe : TAK-1 inhibition disrupts Pim-2-associated and Pim-2-independent key signaling pathways to effectively suppress tumor growth and restore bone formation in myeloma, 第78回日本血液学会学術集会, Oct. 2016.
160.	Masato Miyake, 張君, Kiyoe Kurahashi, 宮本千伸, 津川和江, Miho Oyadomari and Seiichi Oyadomari : 脂肪組織での小胞体ストレスなどで活性化されるeIF2αリン酸化シグナルによる肥満抑制作用, 第89回日本生化学会大会, Sep. 2016.
161.	高橋優花, 山下沙織, Sumiko Yoshida, 桝田志保, Kana Morimoto, Kiyoe Kurahashi, Motoyuki Tamaki, Takeshi Kondo, Akio Kuroda, Tomoyuki Yuasa, Itsuro Endo, Munehide Matsuhisa, Seiji Fukumoto, Hiroyuki Azuma, Masahiro Abe and Ken-ichi Aihara : 生活習慣病患者における血管内皮機能正常群および低下群の臨床指標に関する検討, 第16回日本内分泌学会四国支部学術集会, Sep. 2016.
162.	山上紘規, Kiyoe Kurahashi, Kana Morimoto, Takeshi Kondo, Itsuro Endo, 明比祐子, Sumiko Yoshida, Akio Kuroda, Ken-ichi Aihara, Munehide Matsuhisa, Seiji Fukumoto and Masahiro Abe : バセドウ病を合併したTSH産生下垂体腺腫の一例, 第16回日本内分泌学会四国支部学術集会, Sep. 2016.
163.	遠藤ふうり, Kiyoe Kurahashi, Kana Morimoto, Takeshi Kondo, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Akio Kuroda, 明比祐子, Makoto Funaki, Munehide Matsuhisa, Seiji Fukumoto and Masahiro Abe : 日和見感染を合併したACTH依存性Cushing症候群の1例, 第253回徳島医学会学術集会(平成28年度夏期), Jul. 2016.
164.	Kiyoe Kurahashi, Itsuro Endo, Nakamura Mayuko, Ohnishi Yukiyo, Takeshi Kondo, Aizawa Shinichi, Seiji Fukumoto and Masahiro Abe : カルシウム感知受容体活性型変異による耐糖能異常, 第34回日本骨代謝学会学術総会, Jul. 2016.
165.	布村俊幸, Sumiko Yoshida, Kana Morimoto, Kiyoe Kurahashi, Takeshi Kondo, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa, Toshio Matsumoto and Masahiro Abe : 副腎に接する神経線維腫を合併したレックリングハウゼン病の1例, 第114回日本内科学会四国地方会, May 2016.
166.	Kiyoe Kurahashi, 河野恵理, 宮本千伸, 津川和江, Miho Oyadomari, 木村千寿子, Satoshi Hisanaga, Masatoshi Morimoto, 山川哲生, 谷内秀輔, 張君, Masato Miyake, Masahiro Abe and Seiichi Oyadomari : ラベルフリー測定によるハイスループットスクリーニングを用いた新規インスリン分泌促進薬の探索, 第59回日本糖尿病学会年次学術集会, May 2016.
167.	Sumiko Yoshida, Ken-ichi Aihara, Kana Morimoto, Kiyoe Kurahashi, Takeshi Kondo, Motoyuki Tamaki, Akio Kuroda, Itsuro Endo, 明比祐子, Makoto Funaki, Seiji Fukumoto and Munehide Matsuhisa : 当院検診受診者における筋肉量がメタボリックパラメーターに及ぼす影響の検討, 第59回日本糖尿病学会年次学術集会, May 2016.
168.	Masato Miyake, Kazuna Takahara, 張君, Kiyoe Kurahashi, 宮本千伸, 津川和江, Miho Oyadomari and Seiichi Oyadomari : ATF6βの肥満・糖尿病における役割の解明, 第59回日本糖尿病学会年次学術集会, May 2016.
169.	Kana Morimoto, Ken-ichi Aihara, Sumiko Yoshida, Kiyoe Kurahashi, Takeshi Kondo, Motoyuki Tamaki, Akio Kuroda, Itsuro Endo, Makoto Funaki, Seiji Fukumoto, Munehide Matsuhisa and Masahiro Abe : 減塩による2型糖尿病入院症例の降圧予測指標, 第59回日本糖尿病学会年次学術集会, May 2016.
170.	Sumiko Yoshida, Ken-ichi Aihara, Kana Morimoto, Kiyoe Kurahashi, Takeshi Kondo, Motoyuki Tamaki, Akio Kuroda, Itsuro Endo, 明比祐子, Makoto Funaki, Seiji Fukumoto and Munehide Matsuhisa : 当院検診受診者における筋肉量が高血圧に及ぼす影響の検討, 第5回臨床高血圧フォーラム, May 2016.
171.	Kana Morimoto, Ken-ichi Aihara, Sumiko Yoshida, Kiyoe Kurahashi, Motoyuki Tamaki, Takeshi Kondo, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Masahiro Abe : 血糖管理入院症例における減塩降圧効果と関連する因子および降圧薬に関する検討, 第5回臨床高血圧フォーラム, May 2016.
172.	Kana Morimoto, Ken-ichi Aihara, Sumiko Yoshida, Kiyoe Kurahashi, Takeshi Kondo, Motoyuki Tamaki, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Masahiro Abe : 2型糖尿病患者の塩分制限による降圧効果を規定する因子の検討, 第89回日本内分泌学会学術総会, Apr. 2016.
173.	Ken-ichi Aihara, Sumiko Yoshida, Kana Morimoto, Kiyoe Kurahashi, Takeshi Kondo, Motoyuki Tamaki, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Masahiro Abe : 心筋リモデリングおよび頸動脈硬化症におけるアンジオテンシンII受容体拮抗薬の効果検証, 第89回日本内分泌学会学術総会, Apr. 2016.
174.	山上紘規, Kiyoe Kurahashi, 森本佳奈, Takeshi Kondo, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Akio Kuroda, 明比祐子, Makoto Funaki, Munehide Matsuhisa, Seiji Fukumoto and Masahiro Abe : インターフェロンβ治療中に糖尿病ケトアシドーシスを契機とし，急性発症1A型糖尿病と診断された一例, 第252回徳島医学会学術集会長井記念ホール, Feb. 2016.
175.	森本佳奈, Ken-ichi Aihara, Sumiko Yoshida, Kiyoe Kurahashi, Motoyuki Tamaki, Takeshi Kondo, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa and Masahiro Abe : 2型糖尿病患者における血糖指標と減塩がもたらす血圧低下との連関, 第252回徳島医学会学術集会長井記念ホール, Feb. 2016.
176.	林亜紀, Takeshi Kondo, Itsuro Endo, Kiyoe Kurahashi, Sumiko Yoshida, Seiji Fukumoto, Ken-ichi Aihara and Masahiro Abe : オクトレオチドLARで画像上，下垂体腺腫が消失した先端巨大症の一例, 第113回日本内科学会四国地方会, Dec. 2015.
177.	Masato Miyake, Kiyoe Kurahashi, 森智子, 宮本千伸, 津川和江, 三浦恭子, 北原吉朗 and Seiichi Oyadomari : 小胞体ストレスを減弱させ膵β細胞でのインスリン生合成を促進する新規化合物の同定, 第27回分子糖尿病学シンポジウム, Dec. 2015.
178.	Masato Miyake, 張君, Tetsuya Shiuchi, Kiyoe Kurahashi, 宮本千伸, 津川和江, Miho Oyadomari and Seiichi Oyadomari : 小胞体ストレスなどで活性化されるeIF2αリン酸化シグナルによる摂食調節を介した肥満抑制作用, 第38回分子生物学会年会・第88回生化学会年会合同大会, Dec. 2015.
179.	張君, Masato Miyake, Kiyoe Kurahashi, 津川和江, 宮本千伸, Miho Oyadomari and Seiichi Oyadomari : CRISPR/Cas9 を用いた小胞体ストレス応答伝達タンパク質の検証, 第38回分子生物学会年会・第88回生化学会年会合同大会, Dec. 2015.
180.	Ryosuke Sato, Masato Miyake, 谷内秀輔, 山川哲生, 張君, Kiyoe Kurahashi, Masatoshi Morimoto, Satoshi Hisanaga, Koichi Sairyo and Seiichi Oyadomari : ATF6βは非古典的小胞体ストレス応答として軟骨細胞分化を制御する, 第38回分子生物学会年会・第88回生化学会年会合同大会, Dec. 2015.
181.	張君, Masato Miyake, Kiyoe Kurahashi, 津川和江, 宮本千伸, Miho Oyadomari and Seiichi Oyadomari : CRISPR/Cas9 を用いた小胞体ストレス応答伝達タンパク質の検証, 第10回小胞体ストレス研究会, Nov. 2015.
182.	Masato Miyake, Kazuna Takahara, Masatoshi Morimoto, Kiyoe Kurahashi and Seiichi Oyadomari : ATF6βの肥満・糖尿病における役割, 第10回小胞体ストレス研究会, Nov. 2015.
183.	Masato Miyake, Kiyoe Kurahashi, 森智子, 宮本千伸, 津川和江, 三浦恭子, 北原吉朗, Miho Oyadomari and Seiichi Oyadomari : 小胞体ストレスを標的とした膵β細胞でのインスリン生合成を促進する新規化合物の同定, 第10回臨床ストレス応答学会大会, Nov. 2015.
184.	Ken-ichi Aihara, Sumiko Yoshida, Kana Morimoto, Kiyoe Kurahashi, Takeshi Kondo, Motoyuki Tamaki, Akio Kuroda, 明比祐子, Itsuro Endo, Makoto Funaki, Seiji Fukumoto, Munehide Matsuhisa and Masahiro Abe : 2型糖尿病患者の左室形態および機能における強化インスリン療法の効果, 日本糖尿病学会第53回中国四国地方会, Oct. 2015.
185.	岡田祐輝, Takeshi Kondo, 森本佳奈, Kiyoe Kurahashi, Motoyuki Tamaki, Sumiko Yoshida, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Seiji Fukumoto, Ken-ichi Aihara and Masahiro Abe : 高CPR血症からグリメピリド誤内服を診断し得た遷延性低血糖の一例, 第53回日本糖尿病学会中国四国地方会米子コンベンションセンター, Oct. 2015.
186.	Ken-ichi Aihara, Sumiko Yoshida, 森本佳奈, Kiyoe Kurahashi, Takeshi Kondo, Motoyuki Tamaki, Akio Kuroda, 明比祐子, Itsuro Endo, Makoto Funaki, Seiji Fukumoto, Munehide Matsuhisa and Masahiro Abe : 2型糖尿病患者の左室形態および機能における強化インスリン療法の効果, 第53回日本糖尿病学会中国・四国地方会米子コンベンションセンター, Oct. 2015.
187.	Satoshi Taniguchi, Akio Kuroda, Motoyuki Tamaki, Hwa In, 森本佳奈, Kiyoe Kurahashi, Takeshi Kondo, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Masahiro Abe and Munehide Matsuhisa : CGM iPRO2と人工膵臓STG-55との測定グルコース濃度の比較, 第53回日本糖尿病学会中国・四国地方会米子コンベンションセンター, Oct. 2015.
188.	森本佳奈, Takeshi Kondo, Itsuro Endo, Kiyoe Kurahashi, Motoyuki Tamaki, Sumiko Yoshida, Akio Kuroda, Munehide Matsuhisa, Seiji Fukumoto, Ken-ichi Aihara and Masahiro Abe : 診断まで長時間を要したACTH分泌低下症の一例, 第15回日本内分泌学会四国支部学術集会高知大学, Sep. 2015.
189.	Masato Miyake, 張君, Kiyoe Kurahashi, 宮本千伸, 津川和江, Miho Oyadomari and Seiichi Oyadomari : 小胞体ストレスなどで活性化されるeIF2αリン酸化シグナルによる摂食調節を介した肥満抑制作用, 第58回日本糖尿病学会年次学術集会, May 2015.
190.	Kiyoe Kurahashi, 森智子, 宮本千伸, 津川和江, Miho Oyadomari, Kazuna Takahara, 木村千寿子, Masato Miyake, Toshio Matsumoto and Seiichi Oyadomari : 膵β細胞での脂肪毒性における小胞体ストレス応答の役割の解明, 第58回日本糖尿病学会年次学術集会, May 2015.
191.	Masato Miyake, Kiyoe Kurahashi, 張君, 津川和江, 宮本千伸, Miho Oyadomari and Seiichi Oyadomari : 肥満に伴う脂肪組織での慢性炎症の増悪プロセスへの小胞体ストレス応答経路の関与, 第37回日本分子生物学会年会, Nov. 2014.
192.	Kiyoe Kurahashi, 森智子, 野村明利, Atsushi Ogura, 津川和江, 宮本千伸, Masato Miyake, Miho Oyadomari, Toshio Matsumoto and Seiichi Oyadomari : 飽和脂肪酸は小胞体膜の流動性低下によるPERK経路の活性化を介して膵β細胞におけるインスリン分泌を低下させる, 第86回日本生化学会大会, Sep. 2013.
193.	Kiyoe Kurahashi, 森智子, Akitoshi Nomura, Atsushi Ogura, 津川和江, 宮本千伸, Masato Miyake, Miho Oyadomari, Toshio Matsumoto and Seiichi Oyadomari : ポスター発表飽和脂肪酸は小胞体膜の流動性低下によるPERK経路の活性化を介して膵β細胞におけるインスリン分泌を低下させる, 第86回日本生化学会大会, Sep. 2013.
194.	Masato Miyake, Akitoshi Nomura, Atsushi Ogura, Kazuna Takahara, Ryosuke Sato, Kiyoe Kurahashi, Miho Oyadomari, Hiroshi Inoue and Seiichi Oyadomari : 骨格筋での小胞体ストレスなどからのeIF2αリン酸化はFgf21発現を誘導しエネルギー消費の増加によって食事性肥満を防ぐ, 第86回日本生化学会大会, Sep. 2013.
195.	Ryosuke Sato, Masato Miyake, Kiyoe Kurahashi, Kazuna Takahara, Akitoshi Nomura, 津川和江, Natsuo Yasui and Seiichi Oyadomari : 軟骨異形成症の原因である変異型FGFR3は小胞体ストレスを介して軟骨細胞のアポトーシスを誘導する, 第86回日本生化学会大会, Sep. 2013.
196.	Masato Miyake, Akitoshi Nomura, Kazuna Takahara, Atsushi Ogura, Ryosuke Sato, Kiyoe Kurahashi, Miho Oyadomari, Hiroshi Inoue and Seiichi Oyadomari : 骨格筋における小胞体ストレスなどによるeIF2αリン酸化は全身のエネルギー消費を増加させて肥満を抑制する, 第56回日本糖尿病学会年次学術集会, May 2013.
197.	Kiyoe Kurahashi, 三浦直子, 宮本千伸, 津川和江, 森智子, Miho Oyadomari, Masato Miyake, Atsushi Ogura, Toshio Matsumoto and Seiichi Oyadomari : 膵β細胞における飽和脂肪酸による脂肪毒性に小胞体膜流動性の低下とPERK経路が影響する, 第56回日本糖尿病学会年次学術集会, May 2013.
198.	Seiichi Oyadomari, Taiji Ito, 森智子, Kiyoe Kurahashi, Ryosuke Sato, 宮本千伸, 三浦直子, 津川和江, Miho Oyadomari and 森和俊 : miRNAを介した小胞体ストレス応答はグルコース応答性インスリン分泌に重要である, 第56回日本糖尿病学会年次学術集会, May 2013.
199.	Masato Miyake, Akitoshi Nomura, Kazuna Takahara, Ryosuke Sato, Kiyoe Kurahashi, Miho Oyadomari, Hiroshi Inoue and Seiichi Oyadomari : 骨格筋における小胞体ストレスなどからのeIF2αリン酸化はエネルギー消費を制御して食事性肥満を防ぐ, 第85回日本生化学会大会, Dec. 2012.
200.	Kiyoe Kurahashi, 森智子, Hiroshi Inoue, Atsushi Ogura, 津川和江, Masato Miyake, Hiroshi Inoue, Toshio Matsumoto and Seiichi Oyadomari : 飽和脂肪酸による膵β細胞のインスリン分泌低下には小胞体膜流動性の変化による小胞体ストレスが関与し，PERK経路の活性化により改善される, 第85回日本生化学会大会, Dec. 2012.
201.	Ryosuke Sato, Masato Miyake, Kiyoe Kurahashi, Kazuna Takahara, Akitoshi Nomura, 津川和江, Atsushi Ogura, Hiroshi Inoue, Natsuo Yasui and Seiichi Oyadomari : FGFR3遺伝子異常による軟骨異形成症における小胞体ストレスの関与, 第85回日本生化学会大会, Dec. 2012.
202.	Masato Miyake, Akitoshi Nomura, Kazuna Takahara, Ryosuke Sato, Kiyoe Kurahashi, Miho Oyadomari, Hiroshi Inoue and Seiichi Oyadomari : 骨格筋での小胞体ストレスなどによる eIF2a リン酸化はエネルギー消費を増大させて肥満を抑制する, 第 24 回分子糖尿病学シンポジウム, Dec. 2012.
203.	Masato Miyake, Akitoshi Nomura, Kazuna Takahara, Ryosuke Sato, Kiyoe Kurahashi, Miho Oyadomari, Hiroshi Inoue and Seiichi Oyadomari : 骨格筋での小胞体ストレスなどによる eIF2αリン酸化はエネルギー消費を増大させて肥満を抑制する, 第7回臨床ストレス応答学会大会, Nov. 2012.
204.	Masato Miyake, Akitoshi Nomura, Kazuna Takahara, Atsushi Ogura, Ryosuke Sato, Kiyoe Kurahashi, Miho Oyadomari, Hiroshi Inoue and Seiichi Oyadomari : 骨格筋での小胞体ストレスなどによる eIF2a リン酸化はエネルギー消費を増大させて肥満を抑制する, 第7回小胞体ストレス研究会, Nov. 2012.
205.	Ryosuke Sato, Masato Miyake, Kiyoe Kurahashi, Kazuna Takahara, Akitoshi Nomura, 津川和江, Atsushi Ogura and Seiichi Oyadomari : 小胞体ストレス伝達タンパク質ATF6βは成長軟骨細胞の機能成熟に重要である, 第7回小胞体ストレス研究会, Nov. 2012.
206.	Seiichi Oyadomari, Taiji Ito, 森智子, Robert Zheng, Ryosuke Sato, Kiyoe Kurahashi, Mari Funahashi, 宮本千伸, 三浦直子, 津川和江 and Miho Oyadomari : miRNAを介した小胞体ストレス応答はグルコース応答性のインスリン分泌に重要である, 第55回日本糖尿病学会学術集会, May 2012.
207.	Taiji Ito, 森智子, Robert Zheng, Mari Funahashi, Ryosuke Sato, Kiyoe Kurahashi, 宮本千伸, 三浦直子, 津川和江, Miho Oyadomari and Seiichi Oyadomari : miRNAを介した小胞体ストレス応答はグルコース応答性インスリン分泌に影響する, 第85回日本内分泌学会学術総会, Apr. 2012.
208.	Seiichi Oyadomari, Taiji Ito, 森智子, Robert Zheng, Ryosuke Sato, Kiyoe Kurahashi, Mari Funahashi, 宮本千伸, 三浦直子 and 津川和江 : microRNAを介した小胞体ストレス応答はグルコース応答性のインスリン分泌に重要である, 第23回分子糖尿病学シンポジウム, Nov. 2011.
209.	Seiichi Oyadomari, Kiyoe Kurahashi, Taiji Ito, 森智子, 村橋玲那, Miho Oyadomari and Toshio Matsumoto : 小胞体ストレス応答による小胞体膜恒常性の破綻は膵β細胞の脂肪毒性の原因となる, 第54回日本糖尿病学会学術総会, May 2011.
210.	Kiyoe Kurahashi, Taiji Ito, 森智子, 村橋玲那, Miho Oyadomari, Toshio Matsumoto and Seiichi Oyadomari : 小胞体ストレス応答を介した膵β細胞における脂肪毒性メカニズムの解析, 第22回分子糖尿病学シンポジウム, Dec. 2010.

Et cetera, Workshop:

1.	遠藤ふうり, Sumiko Yoshida, 辻本賀美, 工藤千晶, 安井沙耶, 桝田志保, 三井由香里, Kiyoe Kurahashi, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Masahiro Abe and Seiji Fukumoto : ソマトスタチンアナログ治療中に胆嚢癌を認めた先端巨大症の1例, 第29回臨床内分泌代謝Update in Kochi, Nov. 2019.
2.	工藤千晶, Kiyoe Kurahashi, 辻本賀美, 安井沙耶, 遠藤ふうり, 三井由香里, 桝田志保, Sumiko Yoshida, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Masahiro Abe and Seiji Fukumoto : ニボルマブ投与により3系統の内分泌障害を発症した2例, 第29回臨床内分泌代謝Update in Kochi, Nov. 2019.
3.	辻本賀美, 三井由香里, 工藤千晶, 安井沙耶, 遠藤ふうり, 桝田志保, Kiyoe Kurahashi, Sumiko Yoshida, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Masahiro Abe and Seiji Fukumoto : 免疫関連有害事象の末ロイド治療中ACTH分泌低下症を認めた1例, 第29回臨床内分泌代謝Update in Kochi, Nov. 2019.
4.	Yukari Mitsui, 辻本賀美, 工藤千晶, 安井沙耶, 遠藤ふうり, 桝田志保, Kiyoe Kurahashi, Sumiko Yoshida, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Masahiro Abe and Seiji Fukumoto : 治療拒否により甲状腺クリーゼを繰り返したバセドウ病の1例, 第29回臨床内分泌代謝Update in Kochi, Nov. 2019.
5.	Kiyoe Kurahashi, 青山万里子, Hiromitsu Takizawa, 遠藤ふうり, 三井由香里, 桝田志保, Sumiko Yoshida, 明比祐子, Itsuro Endo, Ken-ichi Aihara, Masahiro Abe and Seiji Fukumoto : 薬物治療に抵抗性で，日和見感染も合併したバセドウ病の一例, 第29回臨床内分泌代謝Update in Kochi, Nov. 2019.
6.	松田宙也, 遠藤ふうり, 三井由加里, 桝田志保, Kiyoe Kurahashi, Sumiko Yoshida, 明比祐子, Itsuro Endo and Seiji Fukumoto : 症状発現から診断までに半年を要したACTH単独欠損症の一例, 第258回徳島医学会学術集会, Feb. 2019.
7.	Hiroyasu Mori, Akio Kuroda, Michiko Araki, Reiko Suzuki, Mami Ohishi, Satoshi Taniguchi, Motoyuki Tamaki, Yuko Akehi, Hiroshi Sakaue, Kiyoe Kurahashi, Takeshi Kondo, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Makoto Funaki and Munehide Matsuhisa : Advanced glycation end-products are a risk for muscle weakness in patients with type2 diabetes., American Diabetes Association 78th Scientific Sessions, Jun. 2017.
8.	Kiyoe Kurahashi, 森智子, 宮本千伸, 津川和江, Miho Oyadomari, Kazuna Takahara, Ryosuke Sato, 木村千寿子, Masato Miyake, Toshio Matsumoto and Seiichi Oyadomari : 飽和脂肪酸は膵β細胞の小胞体膜の組成を変化させ，PERK 経路の活性化による翻訳抑制を介してインスリン分泌を低下させる, 第26回分子糖尿病学シンポジウム, Dec. 2014.
9.	Masato Miyake, Kiyoe Kurahashi, 森智子, 宮本千伸, 津川和江, 三浦恭子, 北原吉朗, Miho Oyadomari and Seiichi Oyadomari : 小胞体ストレス応答を制御する新規化合物によるインスリン生合成の促進, 第9回小胞体ストレス研究会, Jul. 2014.
10.	Ryosuke Sato, Masato Miyake, 松尾顕, 張君, 谷内秀輔, Kiyoe Kurahashi, Kazuna Takahara, Satoshi Hisanaga, Koichi Sairyo and Seiichi Oyadomari : 軟骨分化におけるATF6βの役割, 第9回小胞体ストレス研究会, Jul. 2014.
11.	Kiyoe Kurahashi, 森智子, 宮本千伸, 津川和江, Miho Oyadomari, Kazuna Takahara, Ryosuke Sato, 木村千寿子, Masato Miyake, Toshio Matsumoto and Seiichi Oyadomari : 飽和脂肪酸による膵β細胞の小胞体膜の組成変化は，PERK経路活性化を遷延させ翻訳抑制を介してインスリン分泌を低下させる, 第9回小胞体ストレス研究会, Jul. 2014.
12.	Masato Miyake, Akitoshi Nomura, Atsushi Ogura, Kazuna Takahara, Ryosuke Sato, Kiyoe Kurahashi, Miho Oyadomari, Hiroshi Inoue and Seiichi Oyadomari : 骨格筋における小胞体ストレスなどによるeIF2αリン酸化はFgf21を介したエネルギー消費の増加によって食事性肥満を防ぐ, 第31回内分泌代謝学サマーセミナー, Jul. 2013.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

糖尿病患者の口腔保健行動セルフケア支援に向けた看護プログラムの再改編 (Project/Area Number: 23K09954 )
加齢性サルコペニアへの炎症性サイトカインの関与とTAK1阻害による治療法の開発 (Project/Area Number: 21K07339 )
糖尿病患者の口腔保健行動の看護支援プログラムの再編と効果検証-教育教材の開発 (Project/Area Number: 20K10755 )
The role of calcium-sensing receptors in the regulation of pancreatic beta cell and intestinal epithelial cell function. (Project/Area Number: 18K16234 )
Development of a Diabetes Oral Nursing Program Including a Modified Diabetes Oral Health Assessment Tool for Nurses (M-DiOHAT(c)) (Project/Area Number: 17K12214 )
Search by Researcher Number (30567342)